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The 19th International Symposium on Laboratory Automation and Robotics provided presentations on state-of-the-art
developments in laboratory automation and robotics. The symposium programme included papers and posters on all
aspects of the technology. These comprised: managing laboratory automation (drug discovery); bioanalytical analysis;
managing laboratory automation in drug discovery development and QC laboratory; functional genomics strategies and
high throughput screening; advanced integration strategies; method development and global methods transfer;
compound handling and logistics; combinatorial chemistry and automated synthesis; high throughput LC-MS-MS;
increasing eæ ciency in dissolution testing; lead optimization; strategies for UHTS; increasing throughput for ADME
toxicology; data management/data handling and bioinformatics; using contract laboratories to increase productivity;
assay miniaturization; process optimization; compliance and automationÐ the regulatory perspective; novel high
throughput screening technologies; compliance and automationÐ the industry perspective. Several discussion sessions
were included and activated, and provided interactive communication on a wider range of subjects.
Although the programme was very comprehensive, the Symposium was designed to provide time for both formal and
informal exchange of information. The technical presentations were organized into concurrent sessions with grouped
papers on related topics.
Abstracts for each paper and each poster are included here. Full presentations of several of these papers will appear in
later editions of this journal.
Designing custom automation systems to ￿ t the
needs of early development
Adam M. Fermier, The R. W. Johnson Pharmaceutical
Research Institute, Raritan, NJ, USA
Co-authors: John Troisi, Ramon L. Rodriguez, and James V.
Weber, Michael P. Graham and Erin C. Herita
The pharmaceutical industry is under extreme pressure
to reduce the costs of bringing drugs to market. Thus, to
achieve this goal the entire drug development process
requires continued ® ne tuning and the introduction of
new technologies. Drug discovery has been moving
through this change over the past decade. Drug devel-
opment is now looking at that same daunting task of
increasing throughput while maintaining compliance
and headcount restraints. Custom automation systems
provides one opportunity to attain this goal.
We have been investigating and building custom auto-
mation into our drug development process. For example,
we have modi® ed a Zymark Benchmate for weighing
small quantities (1± 50mg) of dry powders. The addition
of weighing dry powders from a stock tube enables many
advantages and increases the ¯ exibility of the Benchmate.
One application we have been using this robot for is to
weigh individual vials of drug substance into HPLC vials
for subsequent accelerated solid state degradation studies.
This typically requires about 20± 40 weighings for a single
study. A typical degradation program would have a
dozen studies for a single compound. The weighing robot
not only saves time but also oå ers some intrinsic safety
because the analyst is not directly exposed to the
material.
We have also designed a custom automated system to
conduct accelerated degradation studies. These studies
require precise control of sampling and temperature. A
typical degradation study is usually conducted over a
period of weeks. To compare studies in a relative manner
for excipient compatibility studies, these times and
temperatures must be maintained. It is an ideal applica-
tion for automation because of its repetitive nature. The
system allows for 16 reactions to be conducted in parallel.
The software keeps track of temperature and times of
sampling.
In this presentation we will review criteria we have found
to be successful in designing the instrumentation and
identifying processes that would be ideal to automate.
Bringing Caco-2 studies from moderate- to high-
throughput screening
Dawn Alderman, Neurogen Corporation, Branford, CT, USA
High throughput screening (HTS) technologies have
been widely used in many areas of drug discovery.
Human Caco-2 cells provide an in vitro model of
drug bioavailability. They are derived from a colorectal
adenocarcinoma cell line and exhibit functional
characteristics of the lower small intestinal tract.
They diå erentiate as a monolayer with apical and
basal directionality that mimics the intestinal
barrier. Involvement of P-glycoprotein and other active
transport systems expressed endogenously in¯ uence drug
absorption.
Currently, most Caco-2 studies have low to moderate
throughput due to assay complexity. Many diå erent
assay formats exist and are commercially available.
Becton Dickinson provides a 3-day assay system and a
10-day assay protocol. The 3-day system includes a
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61media kit, vital to the growth and diå erentiation of the
cells used within a 3-day period. The 10-day protocol
suggests that the cells can be seeded and used after a 10-
day growth period without the requirement of the
enhanced media necessary for the 3-day system. The
10-day assay media that we currently use has an anti-
biotic in it to protect against the potential bacterial
contamination that may occur with the cells seeded in
the plate for 10 days. The antibiotic condition may aå ect
the data when comparing with the 3-day system. Neuro-
gen is currently evaluating these assays for any potential
diå erences.
The Caco-2 model does not take into consideration ® rst-
pass metabolism. The detection method also creates a
signi® cant bottleneck. Currently LC/MS/MS is being
used. By using HTS technologies, such as laboratory
automation and miniaturization, we have shown that
the throughput of the Caco-2 assay can be signi® cantly
increased. The introduction of the TECAN GENESIS
has allowed the automation of the drug addition to the
Caco-2 assay plates. It has also allowed for automated
sampling. The TECAN GENESIS that is currently in
our facility has 1ml Te¯ on-coated syringes, and a 21-
plate deck design. The programs being used have been
written in-house using the GENESIS software.
We have evaluated the 3-day assay system and are
currently evaluating the 10-day protocol, in 24- and
96-well formats. We have found that our data are of
good quality and are reproducible in-house. We are still
evaluating many aspects of the 96-well assay format.
Eå ective cell density and the volumes used in each assay
format have been assessed. We began by investigating a
couple of cell densities. We have evaluated 12.5K/well
(Becton Dickinson protocol) and 25K/well. Well vol-
umes have also been assessed. Initially 100ml in the apical
ports and 250ml in the basal ports was used. However,
this condition is associated with a suspected wicking
problem. The sample under the plate lid as well as the
volume moving up the interior wall of the basal compart-
ments has been observed. This is a possible suspect for
interwell contamination. We are further developing this
assay and will evaluate this phenomenon. We have
attempted to cut the volumes from 100ml in the apical
compartment to 80ml. The basal well we have cut the
volume from 250 to 200ml.
There are many assay conditions that have been pub-
lished that vary between laboratories. Many publications
suggest that a pH gradient from 6.5 (apical compart-
ments) to 7.4 (basal compartments) is the best model,
representing the conditions of the lower small intestine.
Another assay condition that varies between laboratories
is what concentration of drug to use. High concentrations
of drug create the risk of saturating the P-glycoprotein
transporter as well as the other active transport mechan-
isms. We are currently evaluating our Caco-2 studies in
modi® ed HBSS buå er at 5mm drug concentration using
the pH gradient. Again, cell density is a factor that varies
between laboratories. Becton Dickinson recommends a
cell density in a 24-well plate to be 200K/well and in a
96-well plate to be 12.5K/well. We are currently using
this recommendation for both assay formats discussed.
Currently, samples are evaluated for Papp (apparent
permeability) using this published equation:
Papp…10¡6cms¡1† ˆ …Vd=A†…dC=dT†:
This is a rate distance measurement, where Vd is the
volume of the donor compartment. A is the surface area
of the monolayer, dC is the change in concentration and
dT is the change in time.
The Caco-2 cell model mimics the dynamics of the
human lower small intestinal tract. The potential for this
model to move towards a high-throughput format oå ers
the high-throughput compound screening in the future,
which is essential to modern pharmaceutical develop-
ment. Optimizing the current cell density and volume
speci® cations serve to strengthen this assay format, and is
currently a major hindrance in its development.
Rational approach for selecting extraction par-
ameters for homogenizer-based tablet assay
methods
Alger Salt, GlaxoSmithKline, Research Triangle Park, NC,
USA
This poster will present a rational approach for choosing
extraction parameters, speci® cally homogenizer times
and speeds for tablet test methods that employ the
TPW II workstation or similar homogenization-based
sample extraction procedures. This approach is based
on the assumption that extractions can be modelled using
a ® rst-order rate equation. The extraction pro® le, a curve
showing the amount of drug dissolved versus time, can be
characterized by a single number k, the ® rst-order rate
constant.
The amount of drug extracted at a given time can be
estimated or predicted if the rate constant is known.
Conversely, the amount of time required to reach a given
amount of drug dissolved can be estimated. These
assumptions allow one to model the process and predict
a combination of parameters to ensure that the tablet is
completely dispersed and that the analyte is extracted
quantitatively. A formal protocol can then be designed
and performed to validate the extraction process. The
poster will describe this approach and illustrate it with a
case study.
Introduction of new technology into the pharma-
ceutical quality-control environment: ‘cutting
costs without cutting corners’
Andy Boughey, AstraZeneca, UK
Ever increasing demands at the drug-discovery level in
recent years have lead to signi® cant advances in auto-
mation. This in turn has lead to increasing numbers of
drug candidates and correspondingly more new products
being manufactured, with a subsequent impact on the
Quality Assurance Department.
Automation plays a key role in the future of quality
control. It is recognized that signi® cant cost savings can
be made with the introduction of automation. However,
there are equally important bene® ts to be gained with
respect to cGMP.
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on quality control and the bene® ts and concerns of
introducing new technologies.
It is easy to support the introduction of new technology
when the bene® ts can be expressed in terms of dollars
saved, but what is the true value of improved regulatory
compliance?
High-throughput analysis of free amino acids in
biological matrices
Arthur Rugg, Cereon Genomics LLC, Cambridge, MA, USA
Co-authors: Shaoxia Yu and Lily Li
Traditionally, chromogenic or ¯ uorescent derivatization
(FD) coupled with high-pressure chromatography
(usually 20± 30 min/separation) is used for amino acid
analysis due the amino acids’ lack of UV absorbance. To
detect an alternated change in the levels of free amino
acids through the screening of thousands of biological
samples, the analysis of 20 amino acids using an HPLC/
FD approach is tedious and time consuming. Therefore,
a high-speed 1.5min per sample LC/MS/MS method has
been developed, validated and implemented to analyse
20 free amino acidsÐ in biological matrices.
Multitasking, scalability and ￿ exibility: the Stac-
cato
TM automated workstation
Matt Boeckeler, Neurogen Corporation, Branford, CT, USA
With drug-discovery technology advancing and chang-
ing as rapidly as it is, there is a growing need for
automated equipment to have the capability to change
with these changes in technology. The use of single-
workstation approaches to liquid handling is decreasing
due to the increasing need for a system that can perform
various liquid-handling tasks on the same platform.
The Staccato
TM automated workstation is an extremely
versatile liquid handler with the capabilities of handling
plate formats ranging from 96- to 1536-well plates. The
` Drag and Drop’ architecture of the software allows for
¯ exibility and ease in process development. With the use
of CLARA
TM 2001 software, method development and
system recon® guration become less intensive. Its scal-
ability lends itself to supporting changes in platforms as
emerging technologies arise.
The Staccato
TM system can be equipped or con® gured
with many components and options to ® t your liquid-
handling needs. Using the SciClone ALH as the base
liquid handler, the system can come equipped with a
disposable tip Rapid head, or a small volume ® xed tip
head with 96 or 384 cannula arrays. To augment the
liquid-handling capabilities of the SciClone, up to four
separate Cavro
TM bulk-dispensing manifolds can be
mounted on the head for reagent additions. Liquid
handling can be further enhanced by the addition of an
eight tip, independent Z-axis probe used for various
liquid-handling applications. Integration of the Auto-
stack with the SciClone gives an exceptionally large
storage capacity for unattended operation. The use of
on-board barcode readers in conjunction with the
CLARA
TM Data Manager, gives the system the ability
to track all compound and assay plates entering the
system.
Reformatting chemical libraries with the Staccato
TM
system is very eæ cient. With its large storage capacity
and ¯ exible con® gurations, reformatting can be done
through a variety of methods. Using the Rapid head
con® guration, 300 96-well plates can be reformatted to
75 384-well plates in one 8-h day. Using the small volume
® xed-tip con® guration, one can convert 200 96-well
plates to 50 384-well plates in one 8-h day. Although
® xed tip con® gurations yield less throughput due to
implementation of wash protocols, there are no consum-
able costs. It also gives you the ability to reformat further
from 384- to 1536-well plates, with an even smaller
volume 384-cannula array designed for 1536 applica-
tions.
The independent Z-axis probes provide the ability to
cherry pick select compounds, assemble serial dilution
plates, and manipulate compounds and reagents for
ADMET studies. Performing parallel processing of plate
types using the ` on the ¯ y’ array swap capabilities, the
Staccato
TM is capable of reformatting from 96- to 384-
well plates using the 96-cannula array. After dropping oå
the 96 array, it can then pick up the 384 array and
further dilute or deliver compounds directly to assay
plates for execution with no human intervention.
The presented pipetting specs are based on ® ve trays run
with three transfers performed per tray. A 0.5ml wet
transfer produces excellent precision with an average
%CV of 6.4, and an accuracy range of 1.06± 7.3%. A
0.5-ml dry transfer yields an average precision %CV of
8.6, and an accuracy range of 0.03± 10.1%. Dry transfers
of 1ml yield a precision average %CV of 5.8 and an
accuracy range of ± 1.5 to 4.4%. Volumes > 1ml yield
similar results to the 1-ml numbers.
System use at Neurogen Corporation entails taking in
chemical entities from our existing archive or from our
high-speed synthesis group and performing compound
dilution procedures, or reformatting processes on the
plates and transferring the compounds directly into assay
plates, all within the same method. On this platform, the
system can also build dose± response plates, prepare
compounds for interdepartmental support or execute a
variety of assays.
After compounds are in the proper format and concen-
tration, with the use of the Cavro
TM dispensers, multiple
reagent addition to assay plates can be accomplished
with the proper scheduling of processes. In essence, the
system can take compounds from their starting format
and concentrations, manipulate the plates to accommo-
date assay-speci® c plate formats and conditions, then
proceed to add the appropriate reagents via the Cavro
TM
dispensers, bringing the assay from compound delivery,
through reagent addition. Dispensing by the Cavro
TM
syringes for volumes of 10± 2500ml all yield similar results.
Across plate precision yields an average%CV of 3.8 with
an accuracy range of 1.1± 5.5%. Non-contact dispensing
of reagents eliminates cross-well contamination and with
multiple manifolds, various reagents can be used.
Replication of compound data generated by the 384-
cannula array at a dry transfer volume of 0.5ml is quite
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achieved, but obtainable with acceptable %CV using
particular pipetting methods. Using the same pipetting
methods and comparing data to proven control methods
for drug delivery yields very acceptable %CVs and
correlation.
CLARA
TM 2001 Software is used for scheduling methods
and integrating peripherals into the existing system. It
communicates with adapter modules that translate com-
mands between CLARA
TM and the ICP of the periph-
eral module, triggering program execution of the
instrument. This method of integration makes the scal-
ability of the system much easier and more eæ cient than
previous conventional methods. Upon process comple-
tion, the ICP sends a message back to CLARA
TM
through the adapter to con® rm completion, or send
notice of an error in execution. The system’ s open
architecture, in conjunction with the CLARA
TM soft-
ware, allows for ¯ exibility and ease when modifying or
implementing new assay platforms and technologies.
The CLARA
TM Data Manager gives you the ability to
manipulate and ® lter incoming data with the use of the
Data Manager’ s ZyMap. Data can be con® gured into
text ® les, Excel sheets or directly transported to a
database via ODBC connections. However, the current
version of the Data Manager is unable to catch critical
eventsÐ events that would trigger the data to be sent to
the database, such as an ` end of run’ event. This inability
does not yet allow the direct triggers to export data to a
database. A temporary remedy supplied by Zymark is a
developer’ s kit (a collection of APIs) that gives you the
ability to build your own Data Manager using prede® ned
templates. Using this method could require extensive
time and programming on the user’ s end depending on
the process and data being captured. However, an
updated version of the Data Manager is anticipated to
be released at the end of October that would alleviate this
problem.
Although the Staccato
TM system has many bene® ts and
capabilities for liquid-handling needs, there were some
implementation issues along the way. The biggest setback
experienced was with limitations of the Data Manager.
One of the top reasons for the selection of the Zymark
system over other vendors’ was the ease of database
connectivity and data export. Another issue was in the
design of the ® xed tip arrays. Great care must be taken
not to damage their Te¯ on coating. Any scarring or
scraping of the material will cause variation in pipetting
procedures especially at small volumes. Service for the
most part is good; however, the redesign and complexity
of the system left the need for more time in training of
technicians to come up to speed in the overall workings of
the system.
Overall, Neurogens experience with the Staccato
TM
system has been a good one. All systems have their
bene® ts and drawbacks. The most important thing is
the cooperation and speed of assistance received when
problems do arise and eæ ciency in coming up with
solutions. In this aspect, Zymark has shown dedication
and commitment to their products and customers.
Update from PQRI’s Blend Uniformity Working
Group: balancing workload with batch homogene-
ity assurance
Garth Boehm, Purepac Pharmaceutical Co., Elizabeth, NJ, USA
The Product Quality Research Institute (PQRI) is a
consortium between industry, academia, and FDA,
which aims to provide a scienti® c basis for the develop-
ment of regulatory policy. One of PQRI’ s ® rst initiatives
was to form a Blend Uniformity Working Group
(BUWG) charged with providing a scienti® c basis for
continued development of FDA policy on BU testing.
The BUWG sought wider industry input through a
survey of current BU testing practices, and a public
Workshop. Using this input together with the experience
of the BUWG members and colleagues, a draft proposal
has been developed and re® ned. The proposal provides a
guide for appropriate testing during scale-up and valida-
tion, and for subsequent routine manufacture. The
proposal is based around initially establishing the rela-
tionship between BU testing and strati® ed testing of the
resulting dosage units. The type and amount of testing
recommended during routine manufacture depends on
the outcome and robustness determined from the valida-
tion testing. The BUWG is currently seeking data from
industry to challenge the proposal with real data to
establish the validity of the suggested approach. The
next step will be to seek public comment on the BUWG
proposal.
Views from the past: HTS in the Molecular Bio-
chemistry Department, Glaxo Wellcome, Inc.
Brent Butler, GlaxoSmithKline, Research Triangle Park, NC,
USA
Co-authors: Cole Harris and Steve Blanchard
The pharmaceutical industry saw a tremendous increase
in screening throughput in the 1990s with the intro-
duction of advanced robotics and liquid-handling
systems, as well as homogeneous assay formats conducive
to higher density assay plates. During this time, there
have been numerous debates on the advantages and
disadvantages of centralized versus decentralized screen-
ing sites. There have also been discussions about the use
of large, integrated robotic systems compared with small
bench-top robotics.
Glaxo Wellcome Research Triangle Park has screened in
a decentralized manner using both large automation
platforms and small bench-top systems. In addition, the
screens have migrated from 96- to 384-well plates. This
talk will focus on the lessons learned from the screening
eå ort in the Molecular Biochemistry Department of
Glaxo Wellcome.
Fully automated screening of intracellular cal-
cium using a novel detector
Brian Rasnow, Amgen, Inc., Thousand Oaks, CA, USA
Co-authors: Jack Lile, Karen Kearns, James Treanor and Peter
Grandsard
We have constructed a fully automated high-throughput,
cell-based screening system that measures aequorin lumi-
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concentration. The system uses a modi® ed Zymark
Rapidplate96 pipetting station to add drug candidates
and known modulators to aequorin-expressing cells
grown in microtitre plates. Simultaneous with compound
addition, custom optics and a high-performance chilled
CCD camera added to the Rapidplate96 take an image
sequence of the plate bottom. Compounds that aå ect
calcium entry or release from intracellular stores can be
analysed using this system. Agonists and antagonists can
be detected in the same screen by imaging both during
compound addition and during a subsequent addition of
known agonists.
The 96-channel imaging ¯ ash luminometre is integrated
with a Beckman CO2 incubator, Zymark Twister, tip
store, ORCA robot, and other peripherals to perform
fully automated screening of up to 72 microtitre plates
with a cycle time of several minutes per plate (about
10000 high-content, cell-based assays/system per day).
The system is controlled with Amgen’ s automation soft-
ware (` Synchronicity’ ). Analogue and digital signal pro-
cessing are performed in real time to remove artefacts
from cosmic rays and bad pixels, and normalize any
systematic eå ects from geometrical and biological hetero-
geneity across the plates. This reduces the about 1.5MB/
plate of raw data to about 10kB of time series, which can
be further compressed and the compounds classi® ed using
principal component analysis and other methods.
We have validated the system for ion channel and GPCR
HTS and dose± response characterization, and it has
screened thousands of plates. We will discuss and contrast
its design and performance with other devices that have
comparable capabilities, and explore some of the data
and information processing challenges presented by high-
throughput, high-content screening systems.
Automated production of medicinal agents from
plant matrices
Bruce E. Richter, Dionex Corporation, Salt Lake City, UT,
USA
Co-author: Richard E. Carlson
Interest in the pharmacologically active compounds
found in plant tissues is growing. The extraction tech-
niques normally used to remove these compounds from
plant tissues require long periods and copious amounts of
solvents. Accelerated solvent extraction (ASE) has been
proven eå ective in removing target compounds from a
variety of plant tissues. Using ASE, the extraction of
compounds from medicinal plants is completed in about
15min using only 20 ml solvent. Extraction of the target
compounds may be only a part of the isolation process.
Interfering compounds such as waxes, pigments and
tannins can be coextracted.
These interferences must be removed before the extracts
can be subjected to screening techniques. Solid-phase
extraction (SPE), liquid± liquid extraction (LLE) and
preparative liquid chromatography are the techniques
most often used for removing interferences from plant
extracts. However, these steps are separate and not
coupled with the extraction process.
This presentation will discuss the coupling of ASE with
liquid-handling apparatus to produce plant extracts free
from interfering coextracted compounds. This combined
system produces natural product extracts that are ready
for biological or chromatographic assay. The comparison
of results from this procedure to those obtained without
automation will be discussed.
Determination of cytotoxic e´ ects of di´ erent
compounds using a multiparametric cell-based
cytotoxicity assay
Chandrasekaran Vasudevan, Cellomics, Inc., Pittsburgh, PA,
USA
Co-authors: Oleg Lapets, Nancy Kerkvliet, Greg LaRocca,
Rachael Krally, Lisa Lemmler, Patricia Petrosko, Megan Weiss,
Joseph Zock and Richik Ghosh
In vitro screening of active compounds for toxic eå ects
earlier in the drug-discovery process will help identify
problems and reduce the high failure rate of current
clinical candidates. Cell-based toxicity assays are crucial
in this eå ort, but are limited by the result generated,
usually cell death. Thus, we have developed a more
sensitive multiparameter cell-based cytotoxicity assay
that quanti® es early changes to key aspects of cellular
physiology that can lead to cellular toxicity.
This assay uses our ArrayScan
1HCS System High
Content Screening (HCS) platform that simultaneously
measures changes in nuclear morphology, cell perme-
ability and lysosomal physiology for individual cells, and
also changes in cell density in microplate wells. Dose±
response and time-course data demonstrating the assay’ s
multiparametric nature will be presented for sample
compounds that aå ect the cellular targets in various
cultured cell lines and also rat primary hepatocytes.
Our data show the assay’ s ability to capture cellular
reactions to compounds and correlate multiple toxicolo-
gical indicators at a single-cell level. This assay represents
a distinct advantage for HCS as a screening tool early in
the drug-discovery process.
Development of a high-throughput, homogeneous,
cell-based assay for screening inhibitors of mul-
tiple drug-resistance pumps on FLIPR or FLEX-
Station systems
Christopher Silva, Molecular Devices Corporation, Sunnyvale,
CA, USA
Co-authors: Kelly J. Cassutt, Anne T. Ferguson and Jesse Twu
Multiple drug resistance (MDR) pumps expressed on the
surface of normal cells are involved in eliminating toxic
compounds generated by or exogenously introduced to
the cells. In cancer chemotherapy, these pumps may
become over-expressed by the tumour cells and render
the drug treatment ineå ective following relapse. MDR
pumps are also normally expressed at the blood-brain
barrier (BBB) and as such give the brain ` sanctuary’ from
chemotherapeutic drugs.
Our goal at Molecular Devices is to provide a tool to
screen libraries for compounds that inhibit the MDR
pumps. Such compound leads could be important for
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the therapeutic regimen. The compound leads identi® ed
might also help facilitate the absorption or retention of
other useful therapeutics for disease treatment.
The assay is designed primarily for screening inhibitors
against the two most common MDR pumps, P-glycopro-
teins (P-gps) and multidrug resistance-associated proteins
(MRPs). Both classes of pumps are known to expel a
variety of mechanistically and structurally unrelated
cytotoxic drugs such as anthracyclines, tacanes, vinca
alkaloids, and epipodophyllotoxins as well as some ¯ uor-
escence substrates or indicators from the cells. For a given
assay the compound library is prepared in a 96- or 384-
well plate and allowed to incubate with cells at room
temperature for 15min or longer. The microplate is
placed in the FLIPR or FLEXStation System followed
by addition of the ¯ uorescence indicator by the instru-
ment. The kinetic readout of the results can then be
collected in a real-time mode. The results are expressed as
the change in relative ¯ uorescence units (RFU) over
time, usually 5-8min after the start of the experiment.
Inhibition of the MDR pumps is indicated by the
increase in RFU above the baseline control.
Using the cell line MCF-7/ADR* (resistant to adriamy-
cin), we showed that the baseline change in counts
without inhibitor is nearly zero while 30mm cyclosporin
A (a known inhibitor to P-gp) increased the RFU to
> 5000. These results indicate that the P-gp expression
level is high enough to keep dye completely out of the
cells and the MDR pumps were inhibited eå ectively by
cyclosporin A. Various tumour and non-tumour cell lines
including the parental MCF-7, Caco-2, and T-cell line
CEM were also tested and showed parallel results. Very
little or no DMSO interference to the assay was observed.
We have developed a robust and reproducible homo-
geneous cell-based assay for high-throughput screening of
compound libraries for inhibitors of MDR pumps. The
ease of use inherent in the format with no wash step
involved along with the rich kinetic data previously
unavailable to the large-scale MDR studies indicate that
the FLIPR MDR Assay Kit will be a time-saving and
cost-eå ective tool in HTS screening of inhibitors of MDR
pumps.
Custom hit-picking robotic system
Claude Dufresne, Merck Research Laboratories, Rahway, NJ,
USA
Co-authors: Christopher Napolitano and Keith Silverman
An in-house integrated automated ` cherry picking’
system will be described. It is designed to provide backup
samples of natural products’ ` hits’ to biologists perform-
ing primary screening. The system uses a Tomtec
MegaStor for high-capacity source plate storage. The
system is controlled by custom software, written in Visual
Basic 6.0, and makes use of ActiveX controls for each of
the system components.
Direct analysis of basic drugs in cell culture lysate
using online extraction LC/MS/MS
Claude R. Mallet, Waters Corporation, Milford, MA, USA
Co-authors: Je¡ Mazzeo and Uwe D. Neue
During the last 10 years, pharmaceutical companies have
constantly pushed for shorter analysis time to breach the
1000 analyses per day barrier. With this demand for
high-speed analysis, new techniques such as 96-well
plates, fast gradients or ultrahigh-¯ ow chromatography
are showing promising results.
We have focused on online extraction techniques for
high-throughput analysis. In a previous study we inves-
tigated the potential of online extraction for the analysis
of basic and acidic drugs in rat plasma. Recently, we
have turned our attention to other types of matrices, e.g.
the study of toxicity of drugs in cell cultures used in pre-
and post-discovery phases. Several chemical and physical
lysate methods were evaluated. The extracts were in-
jected onto an extraction column at high ¯ ow rate (i.e.
4mlmin¡1) [1± 3] to remove macromolecular compounds
such as proteins, but trap smaller analytes on the head of
the column. Several con® gurations for direct injection are
possible. In the simplest con® guration, the extraction
column is connected directly to the MS/MS system.
Other versions are con® gured with a single or a dual
extraction column coupled to an analytical column. It is
often necessary to split the ¯ ow. However, in cases where
sensitivity is low, this option is not recommended. For
eæ cient high-speed analysis, the use of a second pump
and a 10-port valve is also a good choice. One line (high
¯ ow rate) can be dedicated to the extraction column,
while the other (low ¯ ow rate) drives the analytical
column and the mass spectrometer.
A three-valve con® guration using two extraction columns
was used for the analysis of basic drugs in cell culture
lysate. The online analysis was performed on an Oasis
HLB extraction column (2:1 £ 30 mm, 25mm) using a
Waters Alliance 2790
TM in the gradient mode and a 515
stand-alone pump in the isocratic mode. The extracted
analytes were forward ¯ ushed into an XTerra column
(2:1 £ 30mm, 3.5mm), which was added to provide
additional separation power. The drugs were quanti® ed
using a MicroMass Ultima
TM triple-quadrupole mass
spectrometer equipped with an electrospray source and
set in multiple reaction-monitoring mode (MRM).
References
1. Xia, Y. Q., Whigan, D. B., Powell, M. L. and Jemal, M., 2000,
Rapid Commun. Mass Spectrom., 14, 105.
2. Ayrton, J., Dear, G. J., Leavens, W. J., Mallett, D. N. and
Plumb, R. S., 2000, J. Chromatogr. A, 828, 199.
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66A look to the future: screening in the Systems
Biology Department, GlaxoSmithKline, Inc.
Cole O. Harris, GlaxoSmithKline, Research Triangle Park, NC,
USA
Co-authors: Brent T. Butler, Steven G. Blanchard and David C.
Morris
Screening at the newly formed GlaxoSmithKline Re-
search Triangle Park site will be heavily dependent on
optimizing the successful processes incorporated over the
previous 5 years in the Molecular Biochemistry Depart-
ment at Glaxo Wellcome. This will require expansion of
the developing approaches to research aided by successful
utilization of existing automation equipment. GlaxoS-
mithKline will compartmentalize these processes to ex-
ploit the bene® ts of speci® c strategies, further de® ning the
process of moving chemistry towards hit identi® cation.
This discussion will focus on accommodating a larger
infrastructure that provides greater target numbers and
larger libraries, as well as complete follow-up screening
using the automation resources available.
Distributing mammalian cell lines for HTS using
the Hydra-96 Microdispenser
Courtney T. Ward, MDS Pharma Services, Bothell, WA, USA
Reliable and consistent distribution of cells into micro-
plates is a key aspect of the performance of cell-based
screening assays. Typically, this has been done using a
hand-held multichannel pipettor in a biosafety cabinet, a
task that is both labor-intensive and slow. We have found
that this step can be accelerated signi® cantly using a 96-
channel pipettor such as the Hydra-96 Microdispenser
whose physical pro® le permits the use of the instrument
in a standard tissue-culture hood. This device consists of
an array of 96 glass syringes (290ml) with ® xed needles
where the plungers move in unison under microprocessor
control. Using four mammalian cell lines, we compared
the pipetting performance of the Hydra-96, a hand-held
pipettor, and a disposable tip-based 96-channel pipetting
workstation. The results indicate that the well-to-well
dispense precision and cell viability are equivalent for all
three devices.
Automated o² ine solid-phase extraction for polar
new chemical entities using the Zymark Rapid
Trace
TM systems
Daksha Desai-Krieger, R. W. Johnson PRI, Springhouse, PA,
USA
A generic automated o¥ine SPE method using the
Zymark Rapid Trace
TM systems was developed for three
very polar new chemical entities (NCEs) undergoing
development at RWJPRI, namely a neuroaminidase
inhibitor, a cephalosporin and a thrombin inhibitor.
The polar characteristics of these compounds made it
impossible to carry out liquid± liquid extraction as a
sample clean-up step for these compounds.
Our goal was to obtain simple automated SPE methods
as sample clean-up for these polar compounds from
biological matrices and develop quantitative LC-MS/
MS assays for these compounds. Challenges encountered
during assay development and details of the method will
be presented. Transfer of these automated o¥ine assays
to online automated SPE and/or o¥ine automated 96-
well SPE will also be discussed.
Development and validation of an automated pool-
ing process for a compliant preparation of blood
plasma pools destined for molecular testing
Danuta Kierek-Jaszczuk, Cangene Corporation, Winnipeg,
Manitoba, Canada
Co-authors: Mike Labossiere, Beverly Belanger, Patti Hosler and
LeeAnne Macaulay
Blood-borne viruses such as HCV, for example, pose a
danger of being transmitted from aå ected donor(s) onto
the recipients of the blood/plasma or thereof derived
pharmaceuticals. The use of nucleic acid testing/nucleo-
tide-ampli® cation testing (NAT) was shown to shorten
the ` window period’ , i.e. a period when donors are in a
state of active but serologically undetectable infection.
When applied to the plasma pools assembled from the
donations destined for the manufacture of the plasma-
based therapeutics, HCV-speci® c NAT would decrease
the risks of HCV transmission onto the recipients of such
therapeutics if virus-contaminated donation(s) are iden-
ti® ed and removed from the fractionation pool.
Accordingly, an automated plasma-pooling process and
pooling-driven back-tracing algorithm have been devel-
oped and validated at Cangene to support the produc-
tion of WinRho and VariZig therapeutics bearing lesser
risk for HCV transmission. The validated Microlab
ATplus 2 automated liquid handler has been used for
the preparation of the plasma mega (master) pools in a
three-stage process where ® nal mega pools were as-
sembled from the intermediary secondary pools and
these, in turn, from the subpools. The automated bar-
code-reading function of the pooling instrument, in a
combination with a suitable barcode-labelling system of
the individual plasma donation- and pool-holding con-
tainers, allowed for the positive identi® cation of both the
individual donations and assembled pools. The pipetting
reports generated by the instrument facilitated a full
traceability of all pipetting events whereas gravimetric
in-process veri® cation assured pipetting accuracy.
A pooling scheme-driven back-tracing algorithm has also
been developed and validated for singling out the indi-
vidual contaminated donation(s). This algorithm in-
volved four-stage back-testing and was based on the
assumption that all NAT-positive test results are true-
positives. It allowed for identi® cation of viral contamina-
tion of a single donation by testing 26 samples, i.e. one
® nal pool, ® ve secondary pools, 12 subpools and eight
individual donations. The developed and validated pro-
cesses allow for cGMP-compliant preparation of the
plasma pools and regulatory required back-tracing of
the viral contamination to individual plasma dona-
tion(s).
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across the screening laboratory
David A. Dunn, Pharmacopeia, Inc.
Co-authors: James R. Beasley, Paul McCoy, Barbara Strohl,
Robert Swanson, Ti¡any Walker and Jingchun Yang
Assay miniaturization and the implementation of high-
density 1536-microwell screening is vital to our need to
increase the eæ ciency of primary screening and early
phase lead discovery. To serve this need, we have
developed a 1536 uHTS platform that employs microwell
plates, novel ¯ uid handling and optical detection tech-
nologies. Full use of this platform requires the ability to
develop assays eæ ciently for a variety of biological targets
in a straightforward and expeditious manner. Having a
portfolio of miniaturizable assay technologies that can be
easily developed into ultrahigh-throughput screens for
any member of a class of biological targets would
enhance and extend the utility of this technology. We
have evaluated a variety of assay technologies that are
suitable for uHTS of kinase and GPCR targets. This
presentation will discuss the relative merits of these
technologies in assembling a portfolio of uHTS assays
for screening these target classes.
Prequali￿ cation of pharmaceutical leads
David Casebier, ArQule, Inc., Woburn, MA, USA
Reliable predictive models and increased throughput of
ADME screens currently enable the design, construction
and pro® ling of chemical libraries, providing con® dence
for series selection in hit-to-lead discovery. Predictive
models for metabolism, absorption, BBB as well as
diversity measurements assist in library design and
reagent selection. Robotic syntheses then generate spa-
tially addressed, high-quality libraries, which in turn are
pro® led for ADME characteristics. Integration of these
technologies allows for the prioritization of lead series
using data indicative of developmental survivability.
Automation of identi￿ cation and screening of
genomic targets related to psychiatric disease
David M. Evans, Psychiatric Genomics, Inc., Gaithersburg,
MD, USA
Psychiatric Genomics, Inc., is interested in discovering
the underlying genetic causes of psychiatric diseases and
identifying therapeutics for them. Many of these diseases
are multigeneic in nature and have not previously been
well characterized owing to the diæ culty in obtaining the
appropriate tissue samples and the lack of technologies
that could detect the changes in gene expression pro® les
within the brain regions.
In recent years, several tools and technologies have been
developed that allow multiple parameters to be tested in
a single experiment. Micro-array technology allows the
discrimination of changes in many genes at one time, and
by comparing ` normal’ versus diseased tissue, it is poss-
ible to identify gene expression patterns quickly that are
altered due to the disease. Having identi® ed the disease
gene pro® le, it is important to be able to develop screens
to examine whether small chemical compounds can
revert the gene pro® le of the diseased state back towards
` normal’ .
This presentation will describe some of the approaches
being taken by Psychiatric Genomics, Inc., to automate
each of the steps in the drug-discovery process using the
new paradigm of automated drug discoveryÐ ` Multi-
Parameter High Throughput Screening’ (MPHTS
TM).
Comparison of ELISA between automation and
manual testing for measuring ARANESPTM in
rat serum
De Chen, Amgen, Inc., Thousand Oaks, CA, USA
Co-authors: Yan Wang, Monica Zordich, Han Gunn and Sharon
Baughman
This presentation compares the results of measuring
ARANESPTM in rat serum, obtained manually or via
a fully automated immunoassay system. ARANESPTM
is a new erythropoietic protein currently used in clinical
trials for the treatment of anaemia related to chronic
renal failure.
The Tecan Genesis workstation 200 was developed to
perform the ARANESPTM quantitative ELISA. It was
equipped with eight pipetting ceramic needles capable of
pipetting 5± 1000ml, a shaking incubator, a Columbus
microplate washer, microplate hotels and a microplate
reader. A robotic arm transported microplates and lids
between the peripherals on the workstation deck.
Seven independent studies were performed on various
days by the TECAN and manually. Standards, quality
controls and known samples were loaded in triplicate on
the plates in each assay. The data generated showed no
signi® cant diå erence. ANOVA analysis con® rmed this
conclusion.
Fully automated systems can be introduced to quantita-
tive immunoassay for protein measurement in serum.
Technical advances in methodologies, robotics and com-
puterization will lead to signi® cant enhancements in the
capacity of immunoassay, resulting in signi® cant cost and
eæ ciency gains.
LC-MS/MS assay for the quantitation of RWJ-
270201 using the Zymark Rapid Trace SPE work-
station
Denise Preston, R. W. Johnson PRI, Spring House, PA, USA
Co-authors: Daksha Desai-Krieger, Virginia Scott and R. John
Stubbs
A simple, automated SPE extraction and LC-MS/MS
assay was developed for the extraction and quantitation
of two NCEs, RWJ-270201 and RWJ-270204, being
evaluated as viral neuroaminidase inhibitors intended
for use in the treatment of in¯ uenza A and B. A solid-
phase extraction method was developed for these analo-
gues using Zymark Rapid Trace SPE workstations.
Extraction of plasma samples was performed using IST
Phenyl SPE cartridges (200mg3ml¡1) conditioned with
methanol and water. Sample clean-up was achieved by
rinsing cartridges with methyl-t-butyl ether. The com-
pounds of interest were eluted using ethanol:water (90:10
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68v/v) and subsequently evaporated under nitrogen to
dryness. The residue obtained was reconstituted before
injection on an LC-MS/MS in the positive-ion APCI
mode.
The developed assay demonstrated good precision and
accuracy and was linear over a broad curve range. The
method developed for these analogues was routinely used
to support preclinical pharmacokinetic studies and was
later adapted for use with 96-well plate technology in
support of clinical studies.
Fully automated protein precipitation LC/MS/MS
assay using a 96-well plate technology and track
robotic system
Scott Paul Depee, GlaxoSmithKline, Research Triangle Park,
NC, USA
Co-author: Brent T. Butler
The need arose in our department to develop a faster and
safer yet user-friendly means of sample preparation
before sample analysis. With shorter mass spectrometer
method run times, the rate-limiting factor was the
sample-processing procedure. To expedite this pro-
cedure, automation through robotics and 96-well plate
technology was implemented. Not only is this robotic
protein precipitation assay process faster than manual
preparation, but also the precision and accuracy are
comparable. In addition, our staå has less exposure to
potential pathogens in the samples, therefore increasing
safety. This robotic system is operated by very user-
friendly software that enables the processing of samples
either in a fully or semi-automated manner. The system
can manage 96 samples in < 1:5h.
Automated o² ine solid-phase extraction for polar
new chemical entities using the Zymark Rapid
Trace systems
Daksha Desai-Krieger, R. W. Johnson PRI, Springhouse, PA,
USA
A generic automated o¥ine SPE method using the
Zymark Rapid Trace( systems was developed for three
very polar new chemical entities (NCEs) undergoing
development at RWJPRI, namely a neuroaminidase
inhibitor, a cephalosporin and a thrombin inhibitor.
The polar characteristics of these compounds made it
impossible to carry out liquid± liquid extraction as a
sample clean-up step for these compounds. Our goal
was to obtain simple automated SPE methods as sample
clean-up for these polar compounds from biological
matrices and develop quantitative LC-MS/MS assays
for these compounds. Challenges encountered during
assay development and details of the method will be
presented. Transfer of these automated o¥ine assays to
online automated SPE and/or o¥ine automated 96-well
SPE will also be discussed.
New technique for a high-throughput solubility
assay
Dima Voloboy, pION, Inc., Woburn, MA, USA
Co-authors: Chau M. Du, M. Stra¡ord, K. Tsinman and A.
Avdeef
We have successfully adapted the classical shake-¯ ask
method to the 96-well microtitre plate format to obtain
near shake-¯ ask-quality results at high-throughput
speeds. The new instrument uses a robotic ¯ uidics system
and a parallel detection system employing a microtitre
plate UV (190-500nm) spectrophotometer. Samples are
introduced as DMSO stock solutions.
The essence of the approach is based on making UV
concentration reference solutions from moleculesÐ espe-
cially ionizable moleculesÐ whose UV spectroscopic
properties are unknown at the start of the assay. This
can be achieved in either of two ways, with or without
cosolvents.
A unique computational method was developed to ex-
tract the aqueous intrinsic solubilities of drug molecules
from data distorted by DMSO drug binding or drug±
drug aggregation reactions.
An improved method for determining concentration by
UV spectrophotometry was derived. It uses a novel peak-
shape algorithm for adjusting weights in a whole spec-
trum-weighted regression analysis, matching spectra of
reference solutions (of known concentration, under con-
ditions avoiding or suppressing precipitation) to solutions
containing an analyte of unknown concentration (due to
precipitation).
A quality-assessment scheme has been developed around
the standard drugs diclofenac, indomethacin, ¯ urbipro-
fen, chlorpromazine, phenazopyridine, verapamil, pirox-
icam and griseofulvin.
The new solubility method, which allows determination
at one pH or as many as 96 pHs, has a limit of detection
of about 0.1mgml¡1, as demonstrated by measurements
of the intrinsic solubilities of terfenadine and tamoxifen.
About 200 assays may be performed per day on the
instrument.
Automated solution-phase synthesis work￿ ow at
Schering AG
Christoph M. Huwe, Schering AG, Berlin, Germany
At Schering we have established a ¯ exible, integrated
solution-phase synthesis, puri® cation and reformatting
work¯ ow based on Chemspeed- and Zymark-automated
synthesizers, parallel normal-phase chromatography as
well as reversed-phase HPLC-MS puri® cation equip-
ment, and a highly automated Zymark reformatting
robot. In this presentation, the special features of the
chosen equipment, the ideas behind the system design
and the respective work¯ ows will be discussed.
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69Intelligent automation of HPLC method develop-
ment
Douglas R. Myers, Intelligent Laboratory Solutions, Naperville,
IL, USA
Co-author: Je¡rey D. DeCicco
Developing new HPLC methods is a time-consuming and
knowledge-intensive task. We have developed an online
software package called ChromSmart that automates
HPLC method development for both normal and re-
versed-phase chromatography for chiral and non-chiral
sample mixtures. Unlike other software packages that
assist with o¥ine HPLC modelling, ChromSmart uses
online arti® cial intelligence technology to capture and
implement the method-development knowledge of expert
chromatographers. ChromSmart contains a real-time
intelligent experiment planner and rule-based engine
that execute the HPLC methods, monitor results and
dynamically update the development plan. A complete
audit trail of the decision-making and results is gener-
ated.
ChromSmart comes with a core set of chromatography
knowledge that automates method development. Based
on user preferences, such as retention times and resolu-
tion, ChromSmart develops a method-development
strategy. This strategy is executed and can dynamically
change based on information from online, real-time
experimental results. Features include automated
equilibration, detection and cleaning of retained
components, gradient and isocratic optimization, peak
purity analysis, and peak tracking. When ChromSmart
® nds a method that meets or exceeds the user’ s criteria, it
noti® es the user and continues to develop another
method for the next sample. ChromSmart operates
24 £ 7£ 365 signi® cantly increasing productivity of
equipment and personnel.
Laboratory automation using Zymark robots and
UV ￿ breoptics from Delphian Technology
Je¡rey B. Medwid, Wyeth-Ayerst Research, Pearl River, NY,
USA
Co-authors: Jerry Edgar, Syed Rahman and Scott Keenan
In the fast-paced pharmaceutical business, quicker turn-
around times and larger sample loads face every analy-
tical laboratory manager. Unfortunately, this must be
accomplished with no signi® cant increase in analyst
resources. Laboratory automation is the only answer.
Our research automation laboratory contains several
Zymark robots including the Multidose Dissolution
Workstations and Tablet Processing Workstations. The
latest addition to our laboratory is a UV Fiber Optic
Dissolution Workstation manufactured by Delphian
Technology. This presentation will highlight some of
our recent work accomplished using these workstations
and some of our other initiatives in automation.
‘Cradle to grave’ tracking of synthetic combina-
torial libraries
Phil Small, Tripos Receptor Research, Bude, UK
A process-integrating design, synthesis and analysis of
combinatorial libraries has been implemented at Tripos
Receptor Research. Crucial to the success of this process
has been the development of a proprietary informatics
system. This has so far been developed to manage reagent
inventory, track samples and record data from synthesis
and analysis to provide a valuable database of compound
information.
The combination of Tripos’ proprietary design software
with automated synthesis and informatics leads to the
production of drug-like libraries with well-de® ned purity
and full synthetic history.
This presentation will cover what were considered the
important aspects involved in setting up and managing
an automated chemistry facility.
Imaging technology in ultrahigh-throughput
screening: overcoming the bottleneck of plate
reader throughput
E. Michael August, Boehringer Ingelheim Pharmaceuticals, Inc.,
Ridge¢eld, CT, USA
Co-authors: Lori Patnaude and Carol A. Homon
Screening throughput is limited by its slowest step, and
thus a major goal of uHTS must be to identify and
overcome these bottlenecks. With the advent of high-
density liquid-handling devices capable of delivering
liquid to 384 or more wells at rates approaching 1
platemin¡1, the bottleneck has shifted from reagent
delivery to plate reading. Conventional plate readers
require several minutes to obtain data from an entire
plate.
Imaging technology allows the detection of an entire
plate simultaneously. Coupled with rapid, sensitive im-
age-analysis software, such a system enables data capture
to keep pace with reagent delivery. We present here
screening results from a recent enzymatic Del® a uHTS
campaign comparing the Wallac Viewlux Imaging
system with the LJL Analyst. Several hundred plates in
both 96- and 384-well formats were read on both readers
and the data were analysed with a variety of statistical
parameters.
Similar comparisons of other assay formats will be
discussed. The inherent ¯ exibility of imaging systems is
highly compatible with assay miniaturization and the
trend to higher-density plate formats. However, we must
also realize that the bottleneck in the overall screening
process has not been removed, but surely shifted to
another step.
Finally the paperless and compliant laboratory
Ed Halpin, VelQuest Corporation, Hopkinton, MA, USA
Compliance and cost have long been at odds in the
modern regulated laboratory. Focusing on one meant
sacri® cing the other. Regulatory compliance today is a
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70labour-intensive, paper-based operation. The ` paperless’
laboratory has been a goal of the pharmaceutical in-
dustry for over the past decade. The con¯ uence of
technology and innovation has reached a point where
the paperless laboratory is now economically and tech-
nologically practical. Good manufacturing practices and
21CFR Part 11 de® ne the requirements to attain a
paperless, compliant laboratory.
The solution would enable direct electronic data capture
from human observations, instruments and networked
PCs replacing paper notebooks, ® les and control sheets.
The solution would enhance the collection of data and
metadata by dynamically linking it to the procedure by
which it was collected. Reviews, audits, investigations
and approvals would be electronic processes, replacing
the current paper systems. Redundant checking would be
replaced by ` review by exception’ and resources reallo-
cated towards the real goal of bringing new human
therapies to the market more rapidly. The solution must
also complement and exchange data with other labora-
tory applications such as Laboratory Information Man-
agement Systems (LIMS) and Chromatography Data
Systems (CDS).
Generating predictive models from high-through-
put pro￿ ling
Dragos Horvath, 128 rue Danton, Rueil Malmaison, France
Co-author: Michael Entzeroth
Current drug development is characterized by a strong
belief in high-throughput methods, both in combinatorial
chemistry and screening. The trigger for constantly
increased performance is the need the industry to adjust
to the race against time in order to secure shares on the
market place. Over many years the industry has tried to
keep pace by the constant introduction of new tech-
nologies. The associated costs for drug development
increased over the last years. Aggregated R&D expendi-
tures for new chemical entities (NCE) peaked in 1996
close to US$500m.1 Recently, Lehman Brothers esti-
mated the total costs for a launched product to account
up to US$635m,2 while for drugs entering clinical trials
between 1972 and 1982 these costs were estimated to add
up to US$312m.3 Research-based companies will invest
$26.4 billion in R&D in 2000, a 10.1 percent increase
over 1999.4 The number New Chemical Entities ap-
proved by the FDA has not changed signi® cantly over
the last years (1997: 39, 1998: 30, 1999: 35), indicating
that the success rate is not related to the initial eå orts.
The portion of IND applications that fail has been
estimated to approximately 20% in phase II, 60% in
phase II and most importantly 87% in phase I.5 83% of
the drugs for which INDs were ® led between 1964 and
1989 were dropped before reaching NDA status.6;7 For
the pharmaceutical companies each dropout during the
development is associated with huge costs that reduce the
pro® t derived from NCEs that reached the market. The
failure of the candidates can be primarily attributed to
eæ cacy, safety and economic concerns. The predominant
reason for failure, however, are inappropriate pharma-
cokinetic properties of the drug candidate (39.4%),
followed by adverse reactions and toxicity that add up
to 21% of the causes for withdrawal from development.
In most of the cases the lack of a complete picture of the
drug’ s properties is not available at the time the decision
to select a respective candidate is taken. In part this is
due to the current process of drug discovery where
information is accumulated stepwise rather than in a
de® ned parallel manner. The choice of the candidate
taken forward is often dominated by emphasizing the
aspect of potency rather than addressing early on selec-
tivity and drug property issues. On the other hand, the
companies have accumulated vast amounts of in-vitro and
in-vivo data that may be used to re® ne the decision matrix
either by retro- or prospective interpretation of existing
results. As a consequence and in order to take the
serendipity out of such fundamental decisions, many
pharmaceutical companies have started broad range
pro® ling (i.e. testing the drugs in parallel against a panel
of diå erent in-vitro model, both in pharmacology and
ADME/PK) in the preclinical phase and have put
emphasis on the development and automation of second-
ary tests. High throughput pro® ling using robotics and
automated workstations allows to accumulate today a
broader knowledge on the hits identi® ed in the primary
screening. Both pharmacologicalÐ speci® city and selec-
tivity versus other targets, such as enzymes and recep-
torsÐ and pharmaceutical propertiesÐ physicochemical
parameters or metabolic and in-vitro safety aspectsÐ of
the candidates are evaluated in depth.8
Through the progress in linking of high-throughput
pharmacological, physicochemical and ` in-silico’ methods
with in-vitro approaches, progress is being made in
predicting drug properties.8 The goal to predict in-vitro
and, ® nally, in-vivo properties of drugs has become
reasonable by linking the chemical structure via mol-
ecular descriptors, area descriptors or ComPharm ® elds
to certain in-vitro pro® les that again can be correlated to
the corresponding in-vivo eå ects (® gure 1).
An example for pharmacophore ® ngerprints are the
Fuzzy Bipolar Pharmacophore Autocorrelograms
(FBPA9) monitoring the numbers of atom pairs within
each of the 252 ˆ 21 £ 12 categories that can be de® ned
in terms of the 21 combinations of six pharmacophoric
features a,b2{Hydrophobicity, Aromaticity, Hydrogen
Bond Acceptor & Donor, Cation, Anion} times 12
considered distance ranges ¢2{(3..4), (4..5), ... ,
(14..15)} [A ® ]. For similarity searches and structural
comparisons, these ® ngerprints are extremely powerful
in combination with ComPharm ® eld descriptors10 that
are taken as the intensities of the empirically de® ned
` pharmacophore ® elds’ generated by the atoms of the
considered compound at the space points occupied by a
reference structure, in a con® guration corresponding to
its optimal alignment with respect to this reference.
The data mining approach described in this report is part
of the BioPrint
TM project11 that makes use of a broad
spectrum pro® ling of marketed drugs and candidates in
more than 90 diå erent in-vitro models. The marketed
drugs, included in the test collection, comprise more than
1,500 compounds that are available in the US pharma-
cies today. Important are also the drug candidates
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71included which have failed to make it all way through the
diå erent phases of preclinical and clinical drug develop-
ment. The models and predictive tools generated open a
new approach for candidate selection and early discovery
activities, such as target identi® cation or library design
and will result in the long term in substantial cost savings
due to reduced failure rates and time spent on the
research and development process. In-silico, linear models
to describe solubility and permeability as well as predic-
tions in pharmacology based on predictive neighborhood
behavior are presented.
Linear ADME models
The interest in an in-silico logD prediction model resides
both in its applicability in library design and its further
use as a calculated molecular descriptor in other struc-
ture-activity relationships, if the activity under study is
expected to relate to the overall lipophilicity of com-
pounds. By contrast to logP models that mostly rely on
incremental group contributions and/or molecular de-
scriptors of the average polarity of the solvent-accessible
surface (an aspect which is in our model successfully
captured in terms of PTA descriptors), a logD model
needs to account for proteolytic eå ects in the aqueous
buå er of pHˆ7.4 used for experimental determinations.
In our models, proteolytic ionization of acids/bases is
implicitly accounted for by the pharmacophore descrip-
tors relying on rule-based assignments of a positive/
negative charge status to ionizable groups. Furthermore,
bipolar pharmacophore elements or ® eld overlap terms
successfully account for potential pKa shifts due to
neighboring groups of the ionizable center.
Linear apparent permeability models
The main challenge in predicting the apparent perme-
ability of compounds through a Caco-2 cell monolayer is
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Figure 1. Predictive modelling of the properties of compounds correlates chemical structures via molecular descriptors with ADME/ëK and
therapeutic e¡ects.
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Figure 2. Predicted versus experimental log D. The properties of compounds from a diverse library of combinatorial compounds (squares)
and medicinal chemistry (circles) were calculated from a model based on a training set of 320 entities (rhomboids).
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72the in-silico recognition of molecules which are trans-
ported by one of the active in- or e¥ux mechanisms.
This will enable the introduction of speci® c correction
factors explaining the diå erence between the actual
membrane crossing rate and the rate expected on the
basis of purely passive transmembrane diå usion. While
the latter aspect of predicting the passive diå usion rates
has been tackled in various publications, little progress
has been made to understand the problem of transported/
e¥uxed compounds, routinely discarded as ` expectable’
outliers in previous work. By contrast, the herein de-
scribed modeling eå ort focused on pharmacophore de-
scriptors in order to search for potential pharmacophore
motifs that may characterize e¥ux and/or transporta-
tion, while descriptors of the molecular surface properties
and the generic calculated logD descriptors were sup-
posed to account for passive membrane crossing proper-
ties. The calculated logD (or, even better, the
experimental logD values) are relevant variables of the
linear log(PA± B) apical-to-basal apparent permeability
model. A positive coeæ cient for the linear contribution,
together with a negative term in logD2 characterize an
optimal logD range maximizing the passive membrane
crossing rate. This makes physical sense, since too hydro-
philic compounds never leave the aqueous phase, while
too hydrophobic ones tend to accumulate in the mem-
branes.
In spite of the important number of bipolar pharmaco-
phore elements entering the model, a series of heavily
e¥uxed compounds are nevertheless mispredicted by the
model and appear as ` false permeable’ . Most of the
outliers in the marked area are shown (® gure 3, circled
area) to be indeed e¥uxed molecules, since their meas-
ured basal-to-apical apparent permeabilities were sig-
ni® cantly higher that the corresponding apical-to-basal
values.
It can be therefore concluded that either (a) e¥ux
cannot be understood in terms of bipolar pharmacophore
descriptors only or (b) e¥ux might in principle be
characterized in terms of such descriptors, but the
number of descriptors that would be required to enter
the model is much larger than the number of examples of
e¥uxed compounds currently included in the data setÐ
note that multiple e¥ux/transportation mechanisms with
potentially diå erent pharmacophore characteristics co-
exist in Caco-2 cells, and that enough compounds
exemplifying each one of them would be required to
solve the problem.
The introduction of ComPharm descriptors overriding
the limitations of bipolar pharmacophore terms is indeed
seen (® gure 3) to signi® cantly improve the permeability
prediction of the outliers from the previous model. These
® eld descriptors were obtained on the basis of super-
imposition models of BioPrint
TM compounds against
some of the most heavily e¥uxed/transported substances
encountered in this set.
Solubility model
A categorical solubility model based on a linear equation
has been developed (® gure 4) in order to predict the
solubility class of the compounds: (1) Low: S < 10 mM;
(2) Medium: 10mM < S < 100 mM; (3) High:
S > 100 mM. This model (not shown here) included 12
explaining variables, such as logD and logD2 and various
Pharmacophore Type Areas (PTA) and bipolar pharma-
cophore elements that predicts drug solubility from its
structural features. With encouraging results it has also
been compared with other solubility prediction software
packages and shown its advantages with 86% of the
drugs predicted in the correct solubility class.
Predictive neighborhood behaviour (PNB) models
By contrast with linear approaches that require a speci® c
equation for each of the properties that are to be
predicted in terms of molecular descriptors, PNB models
rely on the measured properties of related compounds
(e.g. nearest neighbors in descriptors space) from the
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  Figure 3. Improvement of the permeability prediction of e¥uxed compounds due to the use of ComPharm ¢eld descriptors in the model.
Training set (rhombs); test set (squares).
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property value of a new molecule. The PNB algorithm
works in principle like a ` fuzzy data base querying tool’ in
the sense that if molecule X is not included in the
BioPrint database, the BioPrint compounds that are most
similar to X are retrieved and used for the evaluation of
the properties of X. The property of the unknown
molecule is computed as a weighted average of the
experimentally determined properties PN(x) of its near-
est neighbors N(X) from the BioPrint set, where the
weighing factors are decreasing functions of the mol-
ecular dissimilarity scores that de® ne how ` near’ a
neighbor N(X) is with respect to X. These dissimilarity
scores are Dice scores calculated on the basis of FBPA,
PTA and EFO descriptors, the intervening empirical
parameters being speci® cally ® ne-tuned in order to maxi-
mize the predictive power with respect to a particular
property. Figure 5 shows the example in the case of
SCH23390, a D1 receptor ligand, which was not in-
cluded in the original data set, however, tested later for
comparison.
Conclusion
During the last decade technologies such as ultrahigh-
throughput screening and combinatorial chemistry have
signi® cantly contributed to the advances in drug dis-
covery. The increase in R&D costs associated and the
bottlenecks further down the development as well as the
high dropout rates have increased the demand for an
alternative approach. BioPrintTM combines molecular
descriptors, high-throughput pro® ling with in-vivo drug
pro® les. It takes advantage of data mining technologies
to generate predictive models that link the three com-
ponents. These models help to build a eå ective strategy
that will foster drug discovery in the new millenium.
 
Expt. Class ->  H  M  L  Tot.Pred 
Pred. Class:H  265  19  2  286 
Pred. Class:M  15  15  12  42 
Pred. Class:L  0  0  12  12 
Tot.ExptClass  280  34  26  340 
         
Predicted in correct class (green)=(265+15+12)/340=86% 
Predicted in neighboring class (yellow)=(15+19+12+0)/340=13.5% 
Predicted in WRONG class(red)=2/340=0.5% 
  Figure 4. Comparison of the predicted solubility class (vertical) of compounds versus the experimental class (horizontal) using the
BioPrintTM solubility model.
 
Figure 5. Receptor pro¢le of SCH23390, 10·m. (upper) Predicted pro¢le (each bar represents the percentage inhibition in a
pharmacological model ‡RMS prediction error) based on the activity of its nearest neighbours; (lower) experimental data in the same
assay panel.
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Powder-dispensing capabilities to the Zymark
Benchmate system
Erin C. Heritage, R. W. Johnson Pharmaceutical Research
Institute, Raritan, NJ, USA
One of the most fundamental routines for a chemist is
the preparation of samples from dry powdered samples.
There have been many expensive attempts to automate
this process. We demonstrate powder dispensing using
an existing robot workstation and some common
disposables.
Powder dispensing was accomplished by building a
dispensing station on an integrated weighing robotÐ
the Zymark Benchmate. The operating principle of the
station is based on applying a vacuum to an airline
connected to a pipette tip. The system is designed to
transfer dry powder from four-dram vials to 16 £ 100 test
tubes. The user can specify target weight and replications
for each compound through a custom-designed Visual
Basic program.
The sample vial is basically carried to the ® xed location
of the pipette tip, placing the tip into the powder. The
vacuum is applied to the airline and the vial removed.
The vacuum holds a small amount of sample powder on
the pipette tip. A test tube is then moved into position
below the pipette tip, the vacuum is released and the
powder is dispensed into the 16 £ 100 test tube. When
the target weight is reached, sample preparation (e.g.
dilution to concentration and mixing) can then be
accomplished on the same workstation.
uHTS of phosphatases using 2D-FIDA anisotropy
detection
Flora Tang, Sugen, Inc., South San Francisco, CA, USA
Various parameters of ¯ uorescence measurement, such as
translational diå usion, brightness and rotation, have
been widely recognized as readout fully amenable to
homogenous, miniaturized uHTS. A novel detection
system using Evotec’ s FCSplus reader, which combines
the ¯ uorescence-intensity distribution analysis (FIDA)
anisotropy detection with confocal microscopy, provides
a very sensitive and ultrahigh-throughput assay format.
The collaboration between Sugen and Evotec OAI is
focused on phosphatases and has demonstrated successful
adaptation of 2D-FIDA anisotropy detection for phos-
phatase assays at the 1ml/well level. A discussion of this
assay format and the uHTS screening results on the
automated EVOscreen Mark II system for several phos-
phatases will be covered.
Considerations in dissolution automation
G. Bryan Crist, VanKen Technology Group, Cary, NC, USA
Among the future challenges for the pharmaceutical
laboratory exists the necessity to automate dissolution
methods to allow maximum throughput with optimum
compliance. This presentation will provide suggestions
for determining the level of automation needed to obtain
peak performance as well as providing insight into
regulatory compliance issues. Associated topics to be
discussed include: novel dosage forms today and provid-
ing analytical challenges in the future, alternate methods
of analysis, the dissolution apparatus of the future and the
involvement of new analytical approaches. Instrumenta-
tion ¯ exibility will be required in the dissolution labora-
tory of the future to utilize fully pooled sampling
techniques, online UV, online HPLC, capillary electro-
phoresis and even atomic absorption for nutritional
analysis.
Semi-automation to total automation concepts including
in situ methods of analysis will also be discussed. As novel
concepts evolve each day, engineers working with scien-
tists will lead to more eæ cient, better-integrated dissolu-
tion instrumentation in the future.
Update from PQRI’s Blend Uniformity Working
Group: balancing workload with batch homogene-
ity assurance
Garth Boehm, Purepac Pharmaceutical Co., Elizabeth, NJ, USA
The Product Quality Research Institute (PQRI) is a
consortium between industry, academia, and FDA that
aims to provide a scienti® c basis for the development of
regulatory policy. One of PQRI’ s ® rst initiatives was to
form a Blend Uniformity Working Group (BUWG)
charged with providing a scienti® c basis for continued
development of FDA policy on BU testing. The BUWG
sought wider industry input through a survey of current
BU testing practices and a public workshop. Using this
input together with the experience of the BUWG mem-
bers and colleagues, a draft proposal was developed and
re® ned. It provides a guide for appropriate testing during
scale-up and validation, and for subsequent routine
manufacture. The proposal is based around initially
establishing the relationship between BU testing and
strati® ed testing of the resulting dosage units. The type
and amount of testing recommended during routine
manufacture depends on the outcome and robustness
determined from the validation testing. The BUWG is
currently seeking data from industry to challenge the
proposal with real data to establish the validity of the
suggested approach. The next step will be to seek public
comment on the BUWG proposal.
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dissolution
Gerard Schneider, LEC Consulting, Blairstown, NJ, USA
The Sotax AT-70 Smart oå ers the ability to automate
fully both USP Apparatus 1 and 2 dissolution methods.
This system, used in conjunction with other eæ ciency-
driven technologies such as premanufactured medium
and online spectrophotometric analysis of samples, can
profoundly reduce the resources required for conven-
tional dissolution testing while enhancing the consistency
of results. Most importantly, these eæ ciency gains can be
achieved within the parameters of a compliance-con-
scious industry.
The eå ects of implementing such technology will be
discussed. The discussion will address the eå ect that
eæ cient, automated dissolution testing has on the prod-
uct development area, where companies are focussed on
delivering products to market in increasingly less time, as
well as marketed product stability and release labora-
tories where QC managers are asked to reduce sample
turnaround times without increasing resources. Examples
of eæ ciency gains will be given in both cases.
Assay automation: let humans do what they are
good at and take robotics to the limit
Gladys Range, Human Genome Sciences, Rockville, MD, USA
In the automation of any process, there are basic steps
that when carefully suited and applied to a particular
laboratory assay or work¯ ow, serve as a tool for eå ective
automation. Biological validation, time and high-
throughput screening assays are, by nature, very diå er-
ent, and are designed with diå erent criteria in mind. A
biological assay is a complex system designed to yield
biological activity using qualitative measurements. Issues
of cost, amount and quality of reagents, although import-
ant, do not play a paramount role in development. The
biological assay is usually a manual assay that requires
signi® cant change before it is automation ready.
High-throughput assays in contrast are speci® c, fast,
reproducible, low standard deviations, low cost and
usually can be automated as much as mechanically and
humanly possible.
Key elements in assay automation are sample sourcing,
screening design, robotics’ hardware and data manage-
ment. These elements need individual careful analysis, a
master plan and follow-up. A challenge in automation is
to enable individual laboratory personnel to contribute
to the ® ne ongoing activity of building a database by
doing their work without stopping to write in a labora-
tory book or even to enter information in a computer.
These in return will prevent redundancy and will im-
prove accuracy and completeness.
Second-generation laboratory robotics and liquid hand-
lers are now designed to handle very high-throughputs,
very dense formats and very small-volume applications.
Likewise, the recent development of sophisticated ¯ uor-
escence systems operating at longer wavelengths, using
time-resolve signals, and ® breoptics’ technology reduce
read time and facilitate moving away from less desired
chemistries and separation steps. While some of the very
large complex robotics systems could automate the
complete sequence of operations comprising an assay, a
higher level of productivity is achieved by paying careful
attention to the work¯ ow. Determining the optimum
assay conditions, standardizing some of the operations
and selectively introducing automation bring in the best
results and bene® ts.
Improving the quality and speed of automated
sample transfers
Glenn Smith, GlaxoSmithKline, Research Triangle Park, NC,
USA
Co-authors: Jimmy Bruner, Charles Buckner and Bob Biddle-
combe
The quantitative transfer of biological ¯ uids is the
most critical aspect of automated sample preparation.
The sampling of plasma, serum, blood or urine represents
the most diæ cult and time-consuming step in most
bioanalytical extraction procedures. We will present
two practical solutions that address these separate
problems:
. automating ` diæ cult’ sample transfers with higher
quality;
. signi® cantly increasing the processing speed of most
` simple’ sample transfers.
First, most laboratories automate sampling on a mul-
tiple-tip liquid-handling workstation such as a Packard
MultiPROBE
1 or Tecan Genesis
TM. Today, samples are
most commonly transferred from various size tubes to a
deep-well plate or a 96-well solid-phase extraction (SPE)
block. Despite their widespread use, these systems cannot
perform sampling with suæ cient precision and accuracy
for certain applications (e.g. samples containing clots or
other insoluble matter; samples with low or insuæ cient
volumes).
We will show how the integration of an analytical
balance on an x-y-z liquid-handling deck can easily
improve the overall accuracy of assay data. The applica-
tion also allows the workstation to process samples that
would otherwise need to be transferred manually.
Samples are aspirated in parallel then dispensed one at
a time, allowing the balance to capture the exact weight
(ˆ> volume) of each sample that was added to a deep-
well or SPE plate. The data are used to correct auto-
matically for any diå erences in sample weights, usually
by pasting the results directly in the ` dilution factor’
column of an analytical system’ s worklist.
Second, for most other applications in which reliable
transfers are easily achieved without gravimetric con-
® rmation, the speed of sample processing remains a rate-
limiting step. Most systems require about 20± 45 min to
transfer 96 samples. This time is signi® cant and limiting
compared with the 1± 2min required for other steps such
as the addition of a reagent using a 96-channel pipetting
station (e.g. Zymark RapidPlate
TM-96, Tomtec Quadra
96
TM, Apricot PP550
TM).
We will detail how custom sample racks can be used to
speed up tube-to-plate sample transfers dramatically.
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and can be used on any 96-channel pipetting station. The
racks, which consist of complimentary pairs, each hold 48
sample tubes arranged in an alternating (staggered)
sequence. With these racks, 48 samples are transferred
simultaneously and 96 are transferred in as little as 2min.
The racks work with most brands of 13-mm outer
diameter cryotubes and 11-mm outer diameter micro-
centrifuge tubes commonly used in bioanalytical labora-
tories.
With these two inexpensive workstation modi® cations we
can now automate 100% of our applications and sig-
ni® cantly speed up the majority of these assays.
Identi￿ cation of cytokine-regulated genes associ-
ated with infertility and obesity by DNA gene-chip
micro-arrays
Grace Wong, Serono Reproductive Biology Institute, Randolph,
MA, USA
Co-authors: H. Yarovoi, Q. Chen, S. Nataraja, Q. Xu, C. Liu,
W. Mesadie J. Lai, J. Straaubhaar, J. Strickler, M. Tepper,
M. Dreano, G. Garotta, S. Fumero, T. Wells, A. Eshkol and S.
Arkinstall
Although the sequence of the human genome has been
determined, the regulation and function of many genes
remain largely unknown. Cytokines are tightly regulated
soluble proteins transiently produced by cells in response
to immunological stimulation or disease manifestation.
The expression of these proteins has been linked to many
diseases including cancer, AIDS, obesity, autoimmunity,
immunode® ciency and infertility, suggesting that cyto-
kines, their receptors, as well as cytokine-induced genes
are potential targets for new drug development. Micro-
arrays such as gene chips and protein arrays are high-
throughput technologies for drug discovery in the post-
genomic era.
We employed DNA transcriptional pro® ling micro-ar-
rays to detect genes under control of cytokines in selected
experimental models. Hence, in ovarian granulosa cells,
TNF stimulates DNA synthesis but inhibits FSH-induced
oestrogen production. These results suggest that identi® -
cation of TNF inducible ` master control genes’ may
reveal new targets for infertility and possibly other
diseases associated with oestrogen. TNF induces more
than 70 genes in rat ovaries in vivo, including genes for
cytokines, kinases, receptors, transcription factors and
enzymes. In contrast to its inhibitory eå ect on oestrogen
production in the ovary, TNF stimulates production of
this sex steroid in human pre-adipocytes and adipocytes
derived from more than 10 patients. Interestingly, hu-
man pre-adipocytes/adipocytes themselves produce TNF
as well as other cytokines and our data suggest a positive
autocrine/paracrine mechanism for control of oestrogen
production by fat cells. In addition to TNF, 16 cytokines
including LT-a, IL-1, IL-6, IL-11, LIF and oncostatin
M all stimulate oestrogen production in human fat cells.
Other cytokines such as TGF-› 1, TGF-› 2, VEGF,
Rantes, IL-4, IL-10, IL-12, IL-18, CD40 ligand and
TNF-related proteins such as LT-b, TWEAK, RANK
Ligand, APRIL and BAFF have no inducing eå ect.
These results indicate that TNF has diå erential and
cell-speci® c actions on key endocrine mechanisms. Iden-
ti® cation of genes induced or inhibited by TNF and other
cytokines may lead to the discovery of novel targets for
drug development.
CrystalScreen: a novel microplate for automated
protein crystallization
Gunther Knebel, Greiner Bio-One GmbH, Frickenhausen,
Germany
Co-authors: Lajos Nya è rsik1, Patrick Umbach, Martin Horn,
Thomas Przewieslik, Wolfram Saenger, Hans Lehrach, Peter
Opfermann and Holger Eickho¡
The three-dimensional structure of any protein plays a
key role in the process of understanding the exact
function of these macromolecules. One proven approach
to structural information of proteins is based on X-ray
diå raction of single crystals. In the past, automated
crystallization was restricted because a reliable hardware
platform and well-suited microplates for high-throughput
screening were missing.
The Max-Planck-Institute for Molecular Genetics
(MPIMG), the Protein Structure Factory (PSF) and
Greiner Bio-One have collaborated to develop a unique
96-well protein crystallization microplate (Crystal-
Screen
TM) with a standardized microplate footprint for
high-throughput applications. Each of the 96 mother
liquor wells corresponds to three crystallization wells.
This allows checkerboard screening with up to 288
crystallization options per plate to investigate optimal
crystal growth followed by 3D-structure analysis. In
combination with a preformed lid, this microplate en-
ables high-throughput multichannel screening of proteins
in automated systems.
The system in use at MPIMG and PSF allows simul-
taneous sitting-drop and hanging-drop vapour diå usion
crystallization experiments at reduced costs. A huge
storage system for 10000 crystallization microplates and
a pipetting device based on solenoid inkjet technology
enables one to set up a complete plate with 96 crystal-
lization conditions in < 3min. All crystallization wells
are inspected in regular intervals with an automated
camera-based detection system to inspect the crystal
growth.
Seamless integration of information in a pharma-
ceutical development environment: integrating
technology from LabWare, NuGenesis, VelQuest
and Waters
Guy Talbot, Purdue Research Center, Ardsley, NY, USA
This presentation will describe Purdue Pharma’ s ap-
proach to an integrated solution between Laboratory
Information Management Systems (LIMS), Chromato-
graphy Data Systems (CDS), Process Management and
Compliance Systems (PMC) and Scienti® c Data Man-
agement Systems (SDMS). It will describe the vendor-
selection process and how Purdue Pharma created an
environment to produce a best-of-breed information sol-
ution to creating the paperless laboratory. Working
towards the creation of a paperless laboratory has the
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source liberation and an electronic compliance platform
for process management and data review.
This paper will describe the process of working with four
vendors to create a complementary data-management
solution to Purdue Pharma’ s needs. The process of
logging in samples, creating worklists, executing analy-
tical methods, capturing data electronically, storing
electronic records, and submitting reports will be re-
viewed. After data creation, electronic data review will
be discussed enabling electronic ` instant replay’ of la-
boratory information.
The primary bene® ts of this complementary solution
approach hold the following possibilities.
. Increased capacity by liberating valuable resources
from rework loops and the manual data review pro-
cess.
. Leveraging the approach to validation of the overall
solution saving time associated with multiple com-
puter validation plans and execution.
. Promise of reduced time to market for new drugs by
using a paperless environment where possible.
This presentation will describe the challenges, successes
and experiences surrounding the task of integrating
complementary information systems in a pharmaceutical
development environment.
Using laboratory automation to prepare com-
pounds precisely for HTS
Haissam Abdelhamid, Purdue Pharma LP, Cranbury, NJ, USA
Pharmaceutical companies are constantly expanding
their compound inventory and reorganizing their screen-
ing plates in an eå ort to ensure new chemical entities can
be identi® ed as rapidly as possible. Whether these new
compounds come from libraries (focussed or diverse) or
medicinal chemistry eå orts, robotics has become an
essential tool when preparing compounds for high-
throughput screening (HTS). Using robotics to automate
routine laboratory tasks not only increases the rate at
which these activities can be completed, but also reduces
incidents of human error. In our laboratories, we have
integrated several robotic systems to aid in compound
dissolution and HTS plate preparation. These enhance-
ments have saved time and increased the reliability of our
screening inventory, particularly when coupled with our
in-house data-management and inventory tracking soft-
ware. Examples of laboratory automation used at Purdue
over that past year will be presented.
DNA micro-array fabrication and processing:
automation in the laboratory
Katrine Verdun, BIOGEM, Division of Biology, University of
California San Diego, La Jolla, CA, USA
Co-authors: Richard Rouse and Gary Hardiman
The con¯ uence of robotics, biotechnology, computer
sciences and the completion of genome sequencing eå orts
for several organisms have resulted in revolutionary
changes in how biomedical research is carried out. It is
now possible to fabricate high-density arrays of speci® ed
DNA sequences that include every known gene of an
organism on a single glass slide. Labelled RNA or DNA
targets (such as mRNAs obtained from cells, tissues or
organisms under diå erent conditions) can be analysed by
hybridization on the array. Diå erences in the levels of
expression for thousands of genes can thus be assessed all
at the same time in a single, simple experiment. Geno-
mics, informatics and automation are playing increas-
ingly important roles as discovery tools in the basic
biological sciences, and as diagnostic and rational ther-
apeutic aids in the clinical arena. We discuss the use of
automation to increase productivity in micro-array fab-
rication and describe how automated procedures increase
the quality of results in micro-array experimentation.
Use of the Bio-Tek Precision 2000
TM automated
pipetting system for micro-array sample prepara-
tion
Paul Held, Bio-Tek Instruments, Winooski, VT, USA
Co-author: Gavin Picket
The production of micro-arrays requires the spotting of
large numbers of unique DNA fragments onto several
diå erent substrates. While several commercially available
instruments have automated this spotting task, the
sample preparation, culture propagation and mainten-
ance of the DNA library are often performed manually
with multichannel pipettes in 8 £ 12, 96-well, or 16 £ 24,
384-well formats. Manual multichannel pipettes, while
more eæ cient than single-channel pipettes, still represent
a large amount of pipetting with many opportunities for
pipetting errors. Here we describe the use of the Precision
2000
TM automated pipetting system to carry out many of
the necessary pipetting tasks required for the preparation
of samples for micro-array spotting. These steps include:
the propagation of plasmid libraries, PCR reaction
preparation, treatment of PCR products for agarose gel
electrophoresis and the reconstitution of lyophilized
samples before micro-array spotting. The Precision
2000 has a completely con® gurable six-station platform
to hold the required pipette tips, reagent troughs and
microplates (96 and 384 well) for ¯ uid transfer. The
platform is removable, allowing for multi-user friendli-
ness, easy cleaning and set-up of the instrument. The
eight-channel pipette arm moves up and down as well as
side to side, while the platform moves front to back to
provide complete access to all locations on the work
platform and complete con® gurability. The pipette arm
uses a proprietary technology to pick up and seal reliably
any standard tip with individual free-¯ oating barrels that
compensate for tips out of position. An optional rapid
dispense eight-channel manifold, which uses a precise
bidirectional syringe pump to dispense accurately and
rapidly ¯ uids from a large unpressurized reservoir, is also
available. The Precision 2000 has a built-in micropro-
cessor that controls all movements. The ¯ exible software,
both onboard and PC-based, provides complete pro-
gramming capabilities. For more complete automation,
robotics interfaces can be developed using ActiveX
1
software commands. The Precision 2000’ s small size, with
a 15 £ 21-inch footprint and a height of 16 inches, allows
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safety cabinets or chemical fume hoods.
Transposition and validation of a manual method
of sample preparation on the TPWII
He è leéne Brillard, Novartis Pharma, Orle è ans la Source, France
Co-authors: Laurent Frances, Florence Dupas, Samir Haddouchi
and Olivier Garinot
The Analytical Development Laboratory NOVARTIS
that works conjointly with the Pharmaceutical Develop-
ment Department had recently acquired the Zymark
Tablet Processing Workstation, TPWII.
Within this laboratory, analytical methods are developed
to perform manual analysis. Consequently, we developed
a procedure to transfer successfully a manual analytical
method to this robotic system. First, the whole par-
ameters of the TPWII that have an in¯ uence on sample
preparation have been determined and, second, the most
important ones have been pointed out in order that they
be validated. This has led to the establishment of a
transfer protocol, which is in two parts:
. development of the automatic method (study and
optimization of all parameters);
. validation of the automatic method.
Accelerating knowledge transfer for improved
lead-candidate selection
John P. Helfrich, NuGenesis Technologies Corporation, West-
borough, MA, USA
Today’ s modern drug-discovery and development re-
search groups are expected to improve the eæ ciency of
delivering NCEs to the clinic. The new high-throughput
processes are dramatically increasing the raw number of
data sets that must be interpreted for decision support
across a global research team eå ort. The NuGenesis
SDMS database serves as the centralized repository for
analytical reports, compound presentation or summary
documents, project reports, and instrumental raw data.
This database can then be extracted to work in conjunc-
tion with your LIMS, Enterprise Data Management
System and/or local specialized visualization and statis-
tical data software products. If your data sources save or
print, the NuGenesis SDMS platform can get it, auto-
matically save it and allow fast eæ cient utilization across
the entire enterprise. After all, the data become informa-
tion that when eå ectively communicated turns into
critical-path knowledge for decision support in drug
discovery.
Maximum return (strategic investments for high-
throughput screening)
James LaRocque, Wyeth-Ayerst Research, Pearl River, NY,
USA
Advanced technologies theoretically enable modern HTS
laboratories to screen expanding libraries quickly against
a drastically longer list of targets while reducing reagent
costs and maintaining more rigorous quality of results.
Even in large pharmaceutical corporations, however, the
collision of ® scal reality and the cost of state-of-the-art
HTS technologies make getting the most out of capital
investments a critical skill for success. Wyeth-Ayerst
Research has made cost-eå ective investments in Packard
CCS PlateTraks and Wallac CCD imagers, while also
continually upgrading our Zymark-integrated systems
with new components and detectors.
This combination of equipment provides maximum
throughput for 384-well formats and supports the transi-
tion to 1536-well formats with relatively modular units
that can be programmed for multiple tasks. While the
management of individual screening projects is delegated
to individual scientists, the complexity of the automation
infrastructure oå ers ample opportunity for the develop-
ment of specialty skills, creating a well-rounded HTS
staå . By practising both individual initiative and co-
operativity, a relatively small group is empowered to
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well HTS, and rate-based hit characterization.
Automated LC/MS analysis of biomolecules using
ProMass
Je¡ Whitney, Novatia, Princeton, NJ, USA
Co-authors: Mark E. Hail and David J. Detlefsen
The recent increase in genomic and proteomic discovery
has increased the need for high-throughput automated
tools for biomolecule characterization. The ¯ ood of new
protein targets will ultimately demand more eæ cient
tools for the evaluation of expressed proteins for drug
discovery and structural biology studies. ProMass is an
automated biomolecule deconvolution and reporting
program used to process LC/ESI/MS data or single
ESI mass spectra to derive molecular mass information.
We recently integrated ProMass with the ThermoFinni-
gan Xcalibur data system to create a version of ProMass
known as ProMassXcali
TM. ProMassXcali processes en-
tire Xcalibur sample sequences, deconvolutes mass spec-
tra from LC/MS data and produces web-based reports.
ProMassXcali uses a novel cross-platform deconvolution
algorithm known as ZNova
TM. ZNova incorporates a
unique charge-state scoring method that assigns the
charge states of all signals in the ESI mass spectra and
transforms the input ESI mass spectra to produce zero-
charge mass spectra (i.e. molecular mass information).
ZNova incorporates signal-processing techniques and
unique logic that allow application to low charge state
spectra and data of low signal-to-noise ratio. As a result,
ZNova can be used to process data from a wide variety of
biomolecules including large proteins, oligonucleotides,
peptides, etc. In this poster, an overview of the Pro-
MassXcali/ZNova system will be presented along with
selected applications which highlight its utility in a high-
throughput environment.
Automated metabolite con￿ rmation and identi￿ -
cation using LC/MS and intelligent chemometrics
Je¡ Whitney, Novatia, Princeton, NJ, USA
In recent years, drug-discovery researchers have placed
greater emphasis on obtaining qualitative measures of
drug candidate ` quality’ by measuring ADME/Tox
tendencies earlier in the discovery process. This has led
to the development of in-vitro assay methodologies for
measuring metabolic stability, cell permeability, solubi-
lity, toxicity, etc. The challenge today is to automate
fully all aspects of these assays by integrating intelligent
data analysis and interpretation tools into one simple-to-
use solution.
This talk will focus on the analytical methods and
intelligent data analysis approaches we have employed
to assess rapidly metabolic stability and metabolite
identi® cation. With the use of SmartLCMS
TM tech-
nology, we will demonstrate the rapid assessment of
metabolic stability of a compound followed by automatic
detailed re-analysis using on-the-¯ y intelligent data-
analysis techniques. In addition to up-front intelligent
automation, we will illustrate the preliminary results of
our MetLab
TM software suite for back-end chemometric-
based data processing techniques to con® rm automati-
cally expected and unknown metabolites.
Development of a high-throughput biochemical
pro￿ ling platform
Je¡rey Murray, Paradigm Genetics, Inc., Research Triangle
Park, NC, USA
Co-authors: Ioana Popa-Burke and Chris Beecher
Paradigm Genetics, Inc., has industrialized the process of
gene-function discovery for human health, nutrition,
crop production and industrial products. The company
has designed the GeneFunction Factory
TM, an indus-
trial-scale laboratory that explores the function of genes
in organisms by integrating state-of-the-art sequencing
technology with phenotype, metabolite and gene-expres-
sion pro® ling to collect hundreds of data points through a
single technology platform.
The Metabolic Pro® ling group is responsible for monitor-
ing changes in the biochemical pro® les of organisms that
occur over the course of development in response to stress
or induced genetic modi® cations. This is accomplished by
using LC-TOF-MS, GC-TOF-MS and ICP-MS instru-
ments. We describe here the innovative high-throughput
processes developed for the cataloguing, storing in a dry
environment, grinding, dispensing and extraction/deri-
vatization of samples using custom robots, as well as
proprietary instruments such as the ` Mash-A-Matic and
` Buster’ .
Role of automation and robotics in high-through-
put ADME pro￿ ling of potential drug candidates
Kelly M. Jenkins, Bristol-Myers Squibb Co., San Diego, CA,
USA
Co-authors: Robyn A. Rourick, Reginald Angeles, Marianne
Teopaco-Quintos and Daniel B. Kassel
Early determinations of pharmaceutical properties can
serve as predictors of a compound’ s likely developmental
success. Our laboratory has implemented high-through-
put ADME assays that address absorption, metabolism
and physicochemical properties in an eå ort to minimize
discovery to market attrition. While trying to meet the
throughput demands of parallel synthesis, we established
an integrated solution for ADME assays which incorpo-
rates a SAGIAN
TM core system for the determination of
both metabolic stability in human liver microsomes
(HLM) and cytochrome P450 (CYP) inhibition. This
automated solution has allowed an increase in capacity,
throughput and reliability for both ADME assays.
The HLM assay uses a Multimek
TM 96-channel pipettor
for liquid handling. The analysis plates are transferred
o¥ine for ® nal analysis using high-throughput parallel
LC/MS. The CYP inhibition method uses a combination
of liquid handlers and a ¯ uorescence plate reader to
perform a single concentration pro® le assay for 88
compounds. CYP inhibition is measured for both
CYP3A4 and 2D6 isozymes.
This system represents a fully integrated approach in
support of high-throughput ADME evaluation in a drug-
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a plug-and-play approach that combines a series of
modular stations to build a robotic system, which is
¯ exible, upgradable and easily recon® gurable when
assays change or are newly developed. The application
of these strategies as a means of assessing metabolic
stability and CYP inhibition of our combinatorial li-
braries is discussed.
Novel homogeneous FRET-based assay for endo-
peptidase inhibitors: assay development, steady-
state kinetics, high-throughput screening and
miniaturization
Joe Bradley, P¢zer Global R&D, Sandwich, UK
Co-authors: Chris Chambers, Helen Boyd, Emma Faure, Joe
Bradley, Simon Dales, Neil Benson, Wilma Keighley and
Andreas Sewing
The growth in compound numbers and subsequent need
for increases in throughput and reduction in cost are key
drivers of developments in the ® eld of high-throughput
screening. Increasingly, there is a move towards ¯ uores-
cence-based assay technologies, which are ideally suited
for screening because they are versatile, homogeneous
and amenable to both automation and miniaturization.
We developed a novel FRET-based assay to identify
inhibitors of a metallo-endopepidase. This assay uses a
novel substrate with a low Km, thus making it cost-
eå ective for high-throughput screening. We have success-
fully transferred and validated this assay onto our
Robolab linear track-screening platform. A full HTS
campaign was subsequently conducted in 384-well for-
mat, achieving a maximum throughput of 75000 data
points within 24h.
This poster will illustrate the HTS process from assay
development to high-throughput screening using state-of-
the-art technology.
Accelerating knowledge transfer for improved
lead-candidate selection
John Helfrich, NuGenesis Technologies Corporation, Westbor-
ough, MA, USA
Managing and tracking data through the discovery pro-
cess requires a compilation of many diå erent types of
analytical, biological and image output. This includes the
collection, storage and management of relevant scienti® c
information about lead candidates, as well as immediate
access to this information for complete compound docu-
ment creation. Data collaboration across the discovery
arena, even across the entire enterprise, is critical to
making crucial go/no go decisions about subsequent lead
candidate development.
The NuGenesis
1 Scienti® c Data Management System
(SDMS) allows discovery scientists electronically to view,
share, reuse and access data within the laboratory, as well
as throughout the enterprise. You can easily capture
laboratory and report data produced in any Windows-
based software application. These data can be catalogued
automatically and accurately for easy retrieval. Immedi-
ate access to this electronic information is possible from
anywhere around the world using Web technology. This
presentation will focus on the principles of good data
management that allow for pharmaceutical and biotech
discovery facilities to leverage data as an asset, protect
valuable intellectual property and ensure the accurate
and easy creation of complete compound documents
throughout the drug-discovery and development process.
Elutri-Zone MS: a new SPE system for rapid
sample processing and LC/MS analysis
John Janiszewski, P¢zer Global R&D, Groton, CT, USA
Co-authors: R. M. Olech, R. A. Pranis, J. R. Jacobson, C. A.
Perman, B. A. Boman, J. Soldo, R. Speziale, T. W. Astle,
M. J. Cole, J. S. Janiszewski and K. W. Whalen
To increase sample throughput, many recent LC/MS
methods have described techniques to shorten and/or
simplify the chromatography step(s) before MS analysis.
We describe a discrete solid-phase extraction step using
Empore SPE membrane to capture the analyte, followed
by an elution step that features the rapid quantitative
transfer of the elutri zone (pure zone) into the MS. This
application was designed primarily for bioanalytical
support of high-throughput ADME screening.
An SPE Card having the outer dimensions of a microtitre
plate was developed by molding a plastic frame around a
sandwich of 3M Empore sorbent (0.5mm thickness,
8mm particles) and micro® bre support material.
Ninety-six discrete elution zones (7mm diameter, 9mm
centres) were welded into the sheet. The SPE Card was
designed to ® t in a modi® ed cell harvester (Tomtec) that
facilitates SPE processing. The harvester performs sor-
bent activation, load and wash steps. Once the analyte
has been retained, an interference wash is completed and
the plate transferred to an elution device (Elutrix,
Tomtec). Each well was eluted directly into the MS
using ¯ ow rates ranging from 1.0 to 3.0mlmin¡1. A
single HPLC pump delivered eluent composed of 5mm
Ammonium Acetate combined with 50± 90% methanol
or acetonitrile.
The SPE Card and Harvester protocol allow rapid (2±
5min) o¥ine sample clean-up followed by direct elution
into the MS detector. This protocol results in the
concentration of the sample and reduces liquid-handling
steps as dry plates are transferred directly to the Elutrix
for LC/MS processing. Owing to the small particle size of
the Empore sorbent, the SPE Card can mimic the
performance of discrete HPLC columns, similar to those
used in high-throughput sample analysis or in online
clean-up protocols. Relevant parameters and preliminary
results will be described here.
Combined gravimetric and colorimetric method
for the calibration and performance testing of
liquid-handling workstations in a GLP laboratory
John R. Alianti, GlaxoSmithKline, Research Triangle Park,
NC, USA
Co-author: Glenn Smith
Good laboratory practices (GLPs) require that
appropriate calibration and performance testing be con-
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liquid-handling systems. Routine evaluation of the
equipment must be performed to assess both the accuracy
and reproducibility (precision) of liquid transfers.
Additionally, the testing methods and acceptance
criteria must adhere to established company-wide
policies (SOPs). These methods must be sensitive as
well as being robust and practical. Likewise, the data
generated must be easily analysed, interpreted and
documented.
Pipetting accuracy is determined by weighing 96-well
plates (in replicates of three) before and after dispensing
a speci® ed volume of liquid. System accuracy at various
volumes is determined and the results used to calibrate
the workstation as appropriate (e.g. Zymark RapidPlate
Syringe Calibration Factors, Tecan GENESIS Liquid
Classes, Packard MultiPROBE II Performance Files).
The between-tip precision, individual-tip precision and
individual-tip accuracies are all ascertained by sub-
sequent colorimetric testing using a photometric micro-
plate reader. A preformatted Microsoft Excel spreadsheet
containing embedded formulas automatically analyses
the data and generates a report.
The procedure developed combines the simplicity of
gravimetric measurement with the speed of colorimetric
microplate reading. The process is generic and can be
used to assess or compare the accuracy and precision of
any workstation. Automated data analysis and standar-
dized report generation facilitate the process and ensure
regulatory compliance.
Implementing automated sample preparation for
GLP and non-GLP bioanalysis to increase produc-
tivity in a contract research organization
John R. Kagel, Charles River Discovery and Development
Services, Worcester, MA, USA
Co-authors: Larry E. Elvebak, Brian E. Lilley, Jakal M. Amin
and James A. Jersey
Client services for analysis and bioanalysis must: provide
reliable results, meet increasingly aggressive timelines,
meet increasingly lower unit costs and be performed
under appropriate regulatory conditions. Automation
was used successfully to satisfy these criteria regarding
sample preparation for high-throughput LC/MS/MS
GLP and non-GLP bioanalysis in a CRO. The ® rst
phase in automating sample preparation involved pro-
cessing samples in a 96-well format using 96-tip parallel
pipetting workstations (e.g. Tomtec) in an open-access
environment. The impact of this implementation was to
increase productivity by at least twofold. The second
phase in automating sample preparation used a liquid
handler (e.g. Tecan Genesis) for the preparation of
calibration standards and automated reformatting and
dilution of samples from tubes or vials into 96-well plates.
In addition, calibration and compliance issues related to
automated sample preparation will be discussed.
Octave system: a new automated instrument for
the analysis of molecular interactions
Robert J. Kaiser, Prolinx, Inc., Bothell, WA, USA
Co-authors: Karin A. Hughes, Guisheng Li, Deborah D. Lucas,
Kevin P. Lund, Chris Pershing, Douglas A. Spicer, Mark L.
Stolowitz, Jean P. Wiley, Steve Bailey, Michael Baum, Erik
Engstrom, Scott MacInnes, Rich Ward, Craig Yamamoto,
George de la Torre, Lynn Hilt, Charles J. Hutchings, Arturo
Kozel, Terry A. Weeks, Dwight Bartholomew, Rick Carr, Keren
Deng, Jerry Elkind, Tom Martin and John Quinn
Surface plasmon resonance (SPR) technology is a power-
ful, label-free method for the analysis of molecular inter-
actions. Prolinx
1, Inc., has developed a new automated
instrument, the Octave Molecular Interaction Analysis
System, that allows this powerful analytical platform to
become ubiquitous in life-science research and drug-
discovery laboratories. This technological breakthrough
is the result of combining the miniaturized Texas Instru-
ments Spreeta
TM 2000 SPR sensor with the Prolinx
Versalinx
TM Chemical Aæ nity Tools. These technologies
have made possible the development of an instrument of
moderate cost that incorporates eight independent sen-
sors operating in parallel. The sensor surfaces can be
readily and eæ ciently modi® ed with molecular targets,
and exhibit low non-speci® c binding. Samples are intro-
duced to the sensors from standard microwell plates using
an integrated liquid-handling robot. This new instru-
ment will signi® cantly increase the throughput of SPR-
based molecular interaction analysis in basic biological
science and drug-discovery applications.
Increased throughput e‡ ciency with dual-column
technology in LC/MS/MS sample analysis
Kathryn B. O’Mara, GlaxoSmithKline, Research Triangle
Park, NC, USA
Co-authors: Lisa St John-Williams and John A. Dunn
Recent advances in automation have signi® cantly re-
duced the amount of time it takes to prepare clinical
samples for LC/MS/MS analysis. As a result, the eæ -
ciency bottleneck has shifted from sample preparation
time to analytical run time on the mass spectrometer. To
reduce the mass spectrometry analysis time, the use of
dual-column technology was evaluated for three single-
column validated LC/MS/MS methods.
For each of the three methods, the HPLC system was
enhanced with switching valves and the appropriate
programming to allow the unit to function in the dual-
column mode. A semi-automated liquid handler was used
to perform either protein precipitation or solid-phase
extraction using 96-well technology. A triple quadrupole
mass spectrometers was used to acquire data using mul-
tiple reaction monitoring.
The three quantitative LC/MS/MS methods using dual-
column technology are currently being used in a high-
throughput laboratory. Each method has been validated
to demonstrate acceptable accuracy and precision. Ro-
bustness has also been demonstrated by the analysis of
thousands of samples in a GLP environment. For each
method, the analytical run time has been reduced by
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have been increased twofold.
Rapid, e‡ cient method for determining metabolic
stability
Kelly Johnson, Waters Corporation, Milford, MA, USA
Co-authors: John Erve, Andre Dandeneau and Beverly Kenney
Modern drug discovery has been transformed by the
automation of research. The resulting explosion of data
in the discovery pipeline, combined with the pressure to
reduce costs and speed up drug-discovery cycles, provides
a strong demand for fast and selective analytical methods
to produce quality data.
In vitro metabolic stability assays provide a rapid estima-
tion of new chemical entities in the discovery phase of
pharmaceutical development. These multistep assays
routinely incorporate robotic liquid-handling systems to
automate the incubation step of test compounds with
human liver microsomes in 96-well plates. Metabolic
stability is subsequently measured by LC/MS as the
amount of substrate metabolized (expressed as the per-
centage remaining of the initial substrate). The resulting
information is crucial in the selection process in determin-
ing a compound’ s potential ` drugability’ .
Given the large number of samples generated by the
liquid-handling systems in metabolic stability assays,
employing automation and higher throughput in every
step of the assay has become a necessity. This presenta-
tion will demonstrate the use of high-throughput LC/MS
methods to analyse samples produced in a metabolic
stability assay. We will develop LC/MS methods that
signi® cantly increase overall throughput without sacri® -
cing data quality. By incorporating such factors as
parallel sample processing, high sample capacity, alter-
nating column regeneration and smaller diameter col-
umns to reduce cycle times, we can analyse the large
number of samples produced and ultimately help ex-
pedite the drug-discovery process.
Filter-immobilized arti￿ cial membrane (￿ lter-
IAM) permeability assay: a new high-throughput
in vitro drug-absorption model
Konstantin Tsinman, pION, Inc., Woburn, MA, USA
Co-authors: A. Avdeef, D. Voloboy, M. Stra¡ord and B. Kenney
The assessment of passive transport properties of over 20
drug and natural product molecules was made using the
in vitro absorption model based on ® lter-immobilized
arti® cial membranes (® lter-IAM), assembled from phos-
phatidylcholine in dodecane, in buå er solutions at
pH 7.4.
Several of the compounds were lactones extracted from
the roots of the kava-kava plant. Experiments were
designed to test the eå ects of stirring during assays and
the eå ects of varying the assay times.
The highly mobile kava lactones permeated in the order
dihydromethisticin > yangonin > kavain > methisticin >
desmethoxyyangonin. Other molecules in the study
ranked: phenazopyridine>testosterone >propranolol >
ketoconazole >piroxicam >caå eine>metoprolol (pro-
posed BCS internal standard)>terbutaline.
Stirring during assay signi® cantly increased the observed
permeabilities for highly mobile molecules.
In addition to permeability measurements, membrane
retention of compounds was determined. Yangonin,
desmethoxyyangonin, ketoconazole and phenazopyridine
were > 60% retained by the arti® cial membranes con-
taining phospholipids.
The in¯ uence of hydrogen bonding was explored by
determining permeabilities using ® lters coated with do-
decane free of phospholipids. The membrane transport of
phenazopyridine (strong hydrogen-bond donor) is about
twice as fast and retention is about twice reduced in the
inert lipid membranes compared with phospholipid-
based membranes.
In the ® lter-IAM method, concentrations were deter-
mined by microtitre plate UV (190± 500nm) spectro-
photometry and by LC/MS. Higher-throughput was
achieved with direct UV by the use of 96-well microtitre
plate formats and with LC/MS by the use of cassette
dosing (5-in-1).
Seamless integration of information in a pharma-
ceutical development environment: integrating
technology from LabWare, NuGenesis, VelQuest
and Waters
Kurt Roinestad, Purdue Pharma LP, Ardsley, NY, USA
This presentation will describe Purdue Pharma’ s ap-
proach to an integrated solution between Laboratory
Information Management Systems (LIMS), Chromato-
graphy Data Systems (CDS), Process Management and
Compliance Systems (PMC), and Scienti® c Data Man-
agement Systems (SDMS). It will describe the vendor-
selection process and how Purdue Pharma created an
environment to produce a best-of-breed information sol-
ution to creating the paperless laboratory. Working
towards the creation of a paperless laboratory has the
potential to result in signi® cant bene® ts including re-
source liberation and an electronic compliance platform
for process management and data review.
This paper will describe the process of working with four
vendors to create a complementary data management
solution to Purdue Pharma’ s needs. The process of
logging in samples, creating work-lists, executing analy-
tical methods, capturing data electronically, storing
electronic records and submitting reports will be re-
viewed. After data creation, electronic data review will
be discussed enabling electronic ` instant replay’ of la-
boratory information.
The primary bene® ts of this complementary solution
approach hold the possibilities to do the following.
. Increased capacity by liberating valuable resources
from rework loops and the manual data review
process.
. Leveraging the approach to validation of the overall
solution saving time associated with multiple
computer validation plans and execution.
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using a paperless environment where possible.
This presentation will describe the challenges, successes
and experiences surrounding the task of integrating
complementary information systems in a pharmaceutical
development environment.
High-throughput robotic workstation for per-
forming gene-expression assays
Michael A. Kuziora, Gene Logic, Inc., Gaithersburg, MD, USA
Metabolism and growth are dependent on a highly
orchestrated interplay of a variety of proteins within
cells. These proteins function as enzymes in metabolic
pathways, signalling molecules for communication be-
tween and within cells, and as various cellular structural
components. In a disease state, cells often modulate the
amounts of speci® c proteins and may produce new
proteins not normally found in a particular type of cell.
The alterations in the proteome observed in the diseased
state most often result from changes in gene expression
levels within a cell. Gene Logic believes that pharmaceu-
tical companies can reduce the time, risk and cost associ-
ated with drug discovery if they know the expression
levels of genes that play roles in the disease-associated
pathways. Such knowledge may help them discover drug
targets, screen drug leads, and predict toxic and phar-
macological responses to drug leads.
Using the Aå ymetrix, Inc. GeneChip
1 micro-array plat-
form, Gene Logic has measured the expression levels of
thousands of genes from a diverse range of normal and
diseased tissues to create a reference gene expression
database called the Gene Express
1 Suite. The bioinfor-
matic analysis tools incorporated in the Gene Express Suite
facilitate the identi® cation of distinct sets of genes whose
expression is consistently altered in a particular disease
state. The expression patterns of these gene sets become a
molecular ® ngerprint of the disease and thus not only
re¯ ect the disease status of metabolic pathways, but also
could also serve to indicate the eå ect of potential treat-
ments when aå ected cells are exposed to a potential drug.
A primary goal of a pharmaceutical company is to
discover drugs that restore the normal functioning of
the disease-aå ected pathways. In one scenario, a phar-
maceutical company could use the information in the
Gene Express database to identify a small set of genes
that indicate a disease state. The expression of this gene
set is then monitored when an appropriate cultured cell
line that represents a disease state of interest is exposed to
chemicals from a compound library. A potential drug
can be identi® ed for further characterization if, for ex-
ample, it is found to restore expression levels of the gene
set to normal levels.
Unfortunately, the use of large micro-arrays to measure
gene expression of a few genes in a high-throughput
screen is not economically feasible at this time. We
therefore investigated the use of alternative method-
ologies to measure gene expression. Bayer Corporation’ s
Quantigene
TM assay, which uses branched DNA (b-
DNA) for signal ampli® cation, and provides a sensitive
and reproducible method for measuring mRNA levels of
a small number of genes. The assay’ s 96-well plate format
and simple handling procedures makes it highly
amenable to high-throughput robotics. This talk will
describe a Zymark Staccato
TM Workstation designed to
perform the hybridization, ampli® cation and signal-
detection steps of the Quantigene assay.
Multivariate calibration of a UV-VIS ￿ breoptic
probe used for direct measurements in a Zymark
XP-based automated dissolution system
Lars A. Svensson, AstraZeneca, Molnda, Sweden
Co-authors: Rimstedt Eva and Svensk-Ankarberg Anna
Correlation between drug dissolution results obtained by
both liquid chromatography (LC) and ultraviolet-visual
(UV-VIS) spectrophotometry has been performed by
multivariate calibration.
The dissolution of tablets or capsules, stored and exposed
to harsh conditions (high humidity/elevated tempera-
tures) at diå erent degrees, was carried out by an auto-
mated system based on the Zymark XP robot. The
system had the capability of withdrawing samples to be
subsequently prepared into LC vials at the same instance
as an UV-VIS spectrum was recorded via a ® breoptic
probe. The same probe was used in all vessels and could
be attached directly adjacent to the ® lter tip for the
sample withdrawal on one of the robotic hands.
The subsequent multivariate calibration was performed
with Simca-P 8.0 (Umetrics AB, Sweden). Most of the
calibration is explained in two components, with the ® rst
mainly corresponding to the UV spectrum and the
second taking into consideration the baseline oå set.
High-throughput chemistry: an integration of
chemistry, automation and informatics
Li Chen, Ho¡mann-La Roche, Inc., Nutley, NJ, USA
One of many impacts that combinatorial chemistry has
been made in the last decade is to stimulate intellectual
creativity to invent new and more eæ cient ways of
making new compounds. Although much eå ort has been
investigated into developing synthetic methods, auto-
mated synthesizers and analytical tools, the high produc-
tivity of compound library synthesis cannot be achieved
without the integration of chemistry, automation and
informatics into an eæ cient process. I will emphasize
what we have learned in how to establish an infrastruc-
ture that integrates functional modules containing a
diverse set of tools for high-throughput organic synthesis
applications. This modular approach provides the maxi-
mum eæ ciency of combinatorial tool functions to support
multiple project teams for drug lead generation, explora-
tion and optimization.
The agenda includes the following.
. HTOS process design.
. Pro- and post-synthesis automation.
. Synthetic chemistry method.
. HT analysis and puri® cation.
. Data management and chemo-informatics.
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TM: a nano￿ uidic platform for ultra-
high-throughput, massively parallel synthesis,
storage and screening (MPS3)
John R. Linton, BioTrove, Inc., Cambridge MA, USA
The Living Chip
TM is a nanotitre plate consisting of a
uniform and addressable through-hole array. The
though-holes are nominally 300mm square and 500mm
deep, giving each well a 50-nl volume. Proprietary coat-
ings make the surfaces of the plates hydrophobic and the
interior of the wells hydrophilic. This allows the samples
to be held in the wells by surface forces and prevents
sample contamination from adjacent wells. Ten thou-
sand-well chips are currently in use and 100000-well
chips are in production.
Massively parallel mixing of assay components takes
place when chips containing diå erent components are
stacked such that the through-holes align. The chips are
imaged using a CCD array for readouts such as absor-
bance, ¯ uorescence and luminescence. Detection is per-
formed in a transmission geometry, taking advantage of
the bottomless wells. These key features and the sophis-
ticated robotics built by BioTrove allow for the rapid
acquisition of biochemical information, on the order of
107 measurements per day. Combining nanolitre reaction
volumes and a simple interface to microtitre plates, the
Living Chip
TM format conserves compound libraries,
increases analytical capabilities and decreases costs. The
platform has applications in all aspects of drug discovery
from materials’ handling and storage, target ID and
validation, to lead discovery and optimization.
Cell culture in the Living Chip
TM using yeast (S.
cerevisiae) and bacteria (E. coli) shows similar growth
characteristics to cells grown in bulk. Additionally, E.
coli cells expressing GFP inoculated into isolated channels
show no crosstalk.
Diverse biological libraries can be introduced to the chip
using a simple dip loading procedure. This technique was
used by BioTrove collaborator Genofocus to dip load
cells expressing a lipase enzyme library into a Living
Chip
TM. The cells were grown up overnight and then
stacked with a chip containing a tagged substrate so that
wells containing clones with increased lipase activity
yielded a greater ¯ uorescence signal. The ` hits’ were
harvested by a puå of air from a microsolenoid valve
positioned above the well, into a microtitre plate waiting
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Figure 1. The Living Chip
TM: a nanotiter plate. The surfaces are hydrophobically coated and the wells are hydrophilic to contain and
isolate samples.
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Figure 2. 10000 well chips (above) are currently in use and 100000 well chips are in production.
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lipase mutant with a 20-fold higher activity relative to
the wild-type. This screening consisted of 30000 assays
performed by one person in less than 2 days, and would
have taken several scientists weeks using conventional
means.
Next step in miniaturization: submicrolitre assays
in 96-well formats
M. J. Wildey, R. W. Johnson Pharmaceutical Research
Institute, Raritan, NJ, USA
Co-author: C. Fleming
Some of the challenges and goals in many of today’ s
screening laboratories are to investigate, evaluate and
validate new techniques that will enable the reduction in
cost, provide an increase in eæ ciency and strengthen the
quality of screening data. Towards the end of reducing
cost, we have been a Beta test site for a novel 96-well
submicrolitre assay system called Arteas. The architec-
ture of Arteas oå ers a solution to the problem of
evaporation in small-volume assays.
We have successfully performed a ¯ uorescent-based en-
zyme assay in Arteas with a reaction volume of 400 nl.
We successfully reproduced published control IC50s and
routinely generate Z’ -factors in the range 0.6± 0.7. We
will show these data and variability around some tests
performed with actual library compounds. Translation of
this device to production screening will be dependent
upon the successful integration of nanoliquid handling
onto our robotic platforms. Initially, we will integrate
this new liquid-handling option onto our Fast Track
robotic platform. Progress on this translation will be
addressed.
Automated compound dilution and presentation
for determination of IC50 data
Malcolm Willson, Systems Research, GlaxoSmithKline, Steve-
nage, UK
Co-authors: David Brown and David Hayes
Programme-targeted SAR screening within Systems Re-
search at Stevenage calls for a process able to progress
compound activity determination (80 to > 320 com-
pounds/week) in real time, enabling ongoing chemistry
to continue based on known biological activity.
Eæ cient compound dilution and generation of assay
plates is required to meet weekly turn around times for
IC50 and cross-screening data generation.
Comparison of manual across-plate dilution, vertical
dilution down a series of plates and Z-dilutions within a
series of 384-well plates will be discussed.
Use of the twin head Biomek FX uses the ¯ exibility of
both the 96- and 384-tip heads, allowing Z-dilutions, a
very eæ cient method for automated generation of IC50s.
By having space on the stock plates for several extra
compounds, a selected range of ` standards’ covering
several assays can be included to enable assay perform-
ance and automation QC to be monitored for each set of
compounds, along with suæ cient control/blanks for
statistical analysis of assay performance.
Cloning of assay templates reduces IT resource require-
ments for data analysis as templates can be cloned rather
than written from scratch.
If compound numbers increase, the system can be
converted to run vertical dilutions down a series of plates
(diå erent dilution per plate). However, this only works if
the assays are stable enough for the increased length of
assay due to the higher plate numbers.
Conversion to 1536 plates doing Z-dilutions from 384-
well stock plates is also an option that would be possible
when liquid-handling devices can cope with smaller
volumes for assays.
Lead generation and optimization: integrated data
mining and informatics in drug discovery
Charles J. Manly, Discovery Technologies, Neurogen Corpora-
tion, Branford, CT, USA
Drug discovery today includes considerable focus of
laboratory automation and other resources on high-
throughput technologies, but lead generation and opti-
mization to clinical candidates continues to be a lengthy
and costly process. The real bene® t of today’ s tech-
nologies is beyond the exploitation of each individually.
Only recently have signi® cant eå orts focused on eå ec-
tively integrating these complex discovery disciplines to
realize their larger potential. Informatics, computational
chemistry, virtual screening and data mining play a large
role in this integration and in increasing the eæ ciency of
the drug-discovery process.
Figure 3. Isolated wells: all wells loaded with media. Cell
expressing GFP innoculated into wells show no crosstalk after
culturing.
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tion: how to outwit, outplay, outlast
Maria DeGuzman, A¡ymetrix, Inc., Santa Clara, CA, USA
Our experience in automating a genomics’ laboratory for
single nucleotide polymorphism (SNP) detection has
shown us that automation projects are not often com-
pleted in the planned or expected manner. With auto-
mation playing an ever-increasing role in the research
and development laboratory, we will discuss why some
projects succeed while others fail. For instance, what are
the real bottlenecks to address? Does experience make a
diå erence? Is management expectation realistic? What
are the advantages and disadvantages of custom or
commercial automation? What are the roles of the
scientists, engineers, and laboratory managers in such
projects?
The recent completion of our high-throughput screening
project has enabled us to look back objectively and
answer these questions for our genomics’ application.
The high-throughput screening project at Aå ymetrix
began in 1999. The initial goals of the project were to
screen for SNPs across 40 unrelated individuals in an
automated fashion. In the initial stages of this project, the
process), which encompassed sample preparation to
scanning, was done manually. This provided an output
of about 2.3Mb of sequence a week for every 4.5 people.
With the collaborative eå ort of the executive manage-
ment group, the high-throughput screening laboratory,
the engineering group and the bioinformatics group, we
set out to accomplish this task.
Unfortunately, as the project continued, con¯ icts
and diæ culties arose. Each group had its own expecta-
tions for the project that were not necessarily commu-
nicated with the others eå ectively. This led to many
problems including delays, miscommunications, unrealis-
tic expectations, frustration and blame being placed on
one another. In addition, another facet compounded the
already diæ cult process: reality. We found several in-
stances where reality interfered in the development of the
project including budget, time, resources and process
bottlenecks. We also saw evidence of con¯ icts such as
when we needed to decide between 96- or 384-well plates,
tubes or plates, custom or commercial or semi-automa-
tion, or even con¯ icts between the scientists and the
engineers.
Fortunately, we realized many of these issues and
managed them eå ectively. We also proceeded to perfect
the process in other ways using protocol enhancements
and microscaling improvements. This increased our
throughput to 1.4Mb per day for every two people while
reducing reagent costs.
At the conclusion of this project, approximately 25 000
genes were screened covering 8.2Mb of the genome
(including genes, regulatory regions and STSs). Since
most of the projects were tested against 40 individuals, we
screened 24 million bases of dsDNA and identi® ed 15 682
SNPs that have been deposited to the SNP public
database. In addition, much of the software, automation
and protocols developed during this project have been
incorporated into other internal research laboratories.
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development and validation
Maria Styslo-Zalasik, R. W. Johnson Pharmaceutical Research
Institute, Raritan, NJ, USA
Co-author: Kathleen Cirillo-Penn
In the past 10 years, laboratory automation has become
increasingly important for routine chemical analysis
testing in the pharmaceutical industry. The use of
automatization or semi-automated laboratory equipment
can reduce the laboratory ¯ ow-through time of the
samples in the QC area. Likewise, automated and semi-
automated equipment can be used as a tool for research
during method development and validation.
This presentation will illustrate how semi-automated
sample preparation can aå ord rapid optimization of
method parameters during early-stage method develop-
ment and validation. The potential dissolution rate and
solubility issues with high sample concentrations can be
avoided through the evaluation of data from parameter
optimization of the sample preparation using semi-auto-
mated instrumentation. Examples for the use of a stand
alone extractor in an assay/purity method validation will
be presented.
New automated instrument for the characteriza-
tion of biomolecular interactions
Mark L. Stolowitz, Prolinx, Inc., Bothell, WA, USA
Surface plasmon-resonance technology is a powerful,
label-free method for the analysis of biomolecular inter-
actions. However, the use of this technology is limited by
the cost, throughput and complexity of existing instru-
mentation and chemistries. Prolinx has developed a new
instrument that will address these limitations and allow
this powerful analytical platform to become ubiquitous in
life science research and drug-discovery laboratories.
This technological breakthrough is the result of combin-
ing the Texas Instruments Spreeta
1 2000 chip with
Prolinx’ s Versalinx
TM Chemical Aæ nity Tools. These
technologies enabled the development of an instrument
of moderate cost that incorporates eight parallel sensor
surfaces that can be eæ ciently modi® ed with molecular
targets and exhibit low non-speci® c binding. The pre-
sentation will encompass technology, design and applica-
tions of this new instrument.
Automation of an infectivity assay for the quanti-
tative analysis of virus in biopharmaceutical
products
Mervyn Cadette, GlaxoSmithKline, Beckenham, UK
Relative to chemical assays in a pharmaceutical devel-
opment environment, biological assays are relatively ` low
throughput’ in comparison. However, the complexity of
assays associated with biological products is often of a
diå erent magnitude. Biological assays become attractive
automation candidates based upon their complexity
coupled with high demand for their use in biopharma-
ceutical analysis.
The Tissue Culture Infectious Dose 50% (TCID50)
assay was used for the quantitation of viral titres used
in vaccine products.
These assays required sterility, therefore requiring all
equipment to be housed in Class II microbiological safety
cabinets. The TCID50 assay was programmed on a
Tecan RSP 200 using eight disposable-tip liquid-hand-
ling probes in conjunction with a robotic manipulator
arm. Culturing of plates containing tissue culture, to
support the TCID50 assay, was automated using a
Zymark Twister coupled to a Multidrop dispenser.
Scheduling and liquid-handling software were combined
to execute this automated assay. The use of the ` joblist’
function allowed the operator to select from a database of
prede® ned dilutions within the Logic pipetting software.
A formal comparison of the automated TCID50 assay
against the manual TCID50 was performed and proved
comparability.
Integrated approach to high-throughput sample
processing, characterization and puri￿ cation
Michael L. Moore, GlaxoSmithKline, King of Prussia, PA,
USA
The extension of high-throughput synthesis in support of
lead optimization has imposed increasingly stringent
requirements on compound characterization, purity
and accurate concentration determination. We devel-
oped an integrated and highly eæ cient process for
compound analysis, puri® cation and sample processing
with a capacity of 100000 compounds/year at a 20-mg
scale. Puri® cation is driven by ultrahigh-throughput
analytical LC/MS, which minimizes the number of
fractions collected and analysed. Custom software with
a browser-based front end is employed to track samples
and provide the required data to robotic workstations.
Managing laboratory automation in the postge-
nomic era
Michael R. Kozlowski, Axiom Biosciences, San Diego, CA,
USA
The completion of the cloning of the human genome has
provided the drug-discovery community with a wealth of
potential drug targets. At the same time, it has produced
challenges to the way in which drug discovery is done.
Formerly, the mandate of drug discovery was to screen a
relatively small number of well-validated targets against
an immense number of compounds. Now, drug-discovery
scientists are faced with processing a very large number of
minimally validated targets. Most targets were formerly
single proteins, which are amenable to screening in
highly reductionist systems. Now it is clear that most
biological processes, including those contributing to
pathological states, must be the result of complex inter-
actions between proteins. A way must be found to address
this new level of complexity. In addition to these
challenges, the availability of the entire sequence of the
human genome raises expectations for the rapid intro-
duction of more, and better, drugs.
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how we carry out drug discovery, and about drug-
discovery automation, from assay development to AD-
MET pro® ling. This talk will discuss some of these new
approaches.
High-throughput screening inhibition assays to
evaluate the interaction of P￿ zer proprietary com-
pounds with cytochromes P450
Michael West, P¢zer Global R&D, Groton, CT, USA
Co-authors: Larry Cohen, Al¢n Vaz and Shawn Harriman
A ¯ uorescence-based drug interaction assay using recom-
binant CYPs and a cocktail of CYP-speci® c probes in
human liver microsomes was assessed as higher through-
put methods for evaluating the potential for inhibition of
CYP1A2-, CYP2C9-, CYP2C19-, CYP2D6- and
CYP3A4-mediated metabolism. Comparisons of IC50
obtained with the ¯ uorogenic and conventional drug
probes in recombinant CYPs were similar for CYP1A2,
2C9, 2C19 and 2D6, but not for CYP3A4.
Additionally, using a single-point estimated IC50 ap-
proach, compounds that were shown to be inhibitors
using conventional drug probes with human liver micro-
somes were also classi® ed as inhibitors in recombinant
CYPs using the ¯ uorescent probes. For the cocktail
approach, it was shown that the CYP-speci® c reactions
were not altered in the presence of multiple probes as
indicated by no distinguishable eå ect on Km or Vmax. As
expected from this result, the IC50s generated in the
cocktail incubations were in good agreement to those
obtained from individual incubations.
GigaMatrix
TM ultrahigh-throughput screening
platform
Mike La¡erty, Diversa, San Diego, CA, USA
The myriad of microbes inhabiting this planet represent
a tremendous repository of biomolecules for pharmaceu-
tical, agricultural, industrial and chemical applications.
Diversa Corporation has the unique capability of
accessing this microbial diversity by taking a culture-
independent, recombinant approach to the discovery
of novel proteins and small molecules. Diversa’ s discovery
programme uses genes and gene pathways captured from
nucleic acids extracted directly from the environment,
which are then constructed into complex, 109-member
environmental libraries. These libraries often contain
up to 5000 diå erent microbial genomes and, thus,
require high-throughput screening methods to cover their
diversity eå ectively.
Diversa has developed GigaMatrix
TM, a new ultrahigh-
throughput screening platform. GigaMatrix plates have
> 100000 bottomless wells in the same footprint as a
microtitre plate. The platform is automated and capable
of screening 1 billion clones per day. Less equipment time
and manpower are required and assay costs are drama-
tically reduced as compared with traditional microtitre
plate-based screening. The power of the GigaMatrix
platform to discover novel enzymes, small molecules,
protein therapeutics and other bioactive molecules will
be presented.
Building an electronic data-handling, compliant,
foundation for the QA analytical laboratories at
Westborough
Mike Stroz, AstraZeneca, Westboro, MA, USA
A signi® cant portion of QA laboratory activities are
dedicated to compliance and data handling in a paper-
based system. AZ Westborough is implementing an
electronic environment in the laboratories to ensure 21
CFR Part 11 compliance, improve eæ ciency and reduce
costs. The presentation will discuss the applications
selected, and the validation and system architecture
being installed to achieve these goals.
Online SPE by column switching: another form of
bioanalytical laboratory automation
Min Chang, Abbott Labs, Abbott Park, IL, USA
Co-authors: Huong Mai, Anita Shen, Brendan Swaine, Qin Ji
and Tawakol El-Shourbagy
Time event-controlled column switching valves have
been available to analytical scientists since the mid-
1970s. Earlier uses of the column-switching valve in-
cluded removing late elution peaks from the HPLC
run, autosampler sharing, two-dimensional HPLC se-
paration (heart cut), inline ® lter/guard column regenera-
tion, online concentration, unattended column selection
and fractions’ collection. Although there is at least one
column-switching valve in an HPLC system (the injector
valve), the idea of the addition of another valve has not
been widely accepted. Analytical scientists have turned
away from the technology possibly due to the lack of
ruggedness of the ® rst-generation air-actuated valve and
other additional pieces of HPLC equipment including
columns.
Recently, with the availability of commercial online
solid-phase extraction system(s), the column-switching
technique has become an acceptable option for bioana-
lytical sample preparation. At Abbott Laboratory, we
have developed several online solid-phase extraction
HPLC methods using automated valves, an internal
reversed-phase guard cartridge and HPLC equipment
by Shimadzu and Agilent. Internal standard forti® ed
plasma were clari® ed by either centrifugation or ® ltered
before the HPLC injection. These methods have been
used successfully to analyse two Abbott compounds and
their metabolites. This application of automated column-
switching valves has provided an alternative to o¥ine
solid-phase extraction and liquid± liquid extraction and
made it possible to select the best technology to increase
assay throughput and sensitivity.
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laboratories
Muhammad Albarakeh, Barr Laboratories, Inc., Pomona, NY,
USA
Co-authors: Richard Ashley and Timothy Breuninger
Current laboratory demands related to the high through-
put of samples, the need to keep costs and expenses
minimal, yet keep the release function ¯ owing to prevent
product backorder, have necessitated the use of labora-
tory automation and robotics systems. As a result of this
automation, huge amounts of samples and related data
are processed and generated.
Without a properly controlled and validated system, the
very tools implemented to process high amounts of
samples can bring your release function to a halt. Over-
views on how to prevent cGMP logs jam and reach a
` zero backorder’ release of product will be presented.
Methods’ development for monoclonal antibody
screening: how to think like a robot
Nanci E. Donacki, MedImmune, Inc., Gaithersburg, MD, USA
A single fusion for the development of monoclonal
antibodies will often generated 20 or more microplates
that need to be screened. ELISA (enzyme-linked im-
munosorbent assay) is the most common method for
screening newly developed monoclonal antibodies for
antibody production and speci® city. The method,
although speci® c for the antibodies, is highly repetitive
for each step and can easily be automated. However, the
way the assay is performed at the benchtop is not always
the best way for an automated system to run the assay.
Tips and techniques for transferring an assay from bench-
top to automation will be presented.
Lean manufacturing and six sigma: an evaluation
of the impact of these concepts on laboratory
automation
Nigel North, Pharmaceutical Development, GlaxoSmithKline,
Ware, UK
The concepts of lean manufacturing and six sigma are
now beginning to be applied to pharmaceutical manu-
facturing processes. Lean manufacturing has been suc-
cessfully applied for many years in the automotive and
aerospace industries with the key goal of reducing waste.
Six sigma is a more recent concept involving reducing
variation in manufacturing processes which has been
implemented in the semiconductor industry resulting in
signi® cant cost savings. The combination of lean manu-
facturing and six sigma provides a powerful combination
of principles to deliver robust manufacturing processes
with the elimination of non-value-added activities. The
eå ect of these concepts on how we approach automation
in the laboratory will be examined together with provid-
ing some perspectives on new technology that will be
required to meet these challenges.
Applications of the Zymark Staccato for in vitro
drug metabolism studies
Heather Sulkowski, Boehringer Ingelheim Pharmaceuticals, Inc.,
Ridge¢eld, CT, USA
Co-authors: J. Richard Mount¢eld, Donald Tweedie and Drane è
O’Brien
Advances in genomics, combinatorial chemistry and
pharmacology screening have led to new challenges
within drug metabolism due to large numbers of com-
pounds requiring in vitro evaluation. To meet these
demands within Boehringer Ingelheim Pharmaceuticals,
Inc., the Zymark Staccato was evaluated as a robotic tool
for conducting multiple in vitro assays. The criteria for an
automated system included the following.
. A 96-well head allowing for maximum sample
throughput.
. Thermal block to maintain constant temperature.
. Flexible deck layout.
. Open-access capability
As part of the evaluation process, assays were compared
using both manual and automated methods. The results
are described in this presentation
Automation of several key in vitro metabolism assays has
been achieved. The results indicate that the automated
assays allow for a higher throughput while maintaining a
high degree of precision. The work will be extended to
additional in vitro assays, and the strategy of comparing
manual versus automated processes will be continued as
part of the validation procedures.
Analytical method validation: an automated soft-
ware approach
Patricia A. Fowler, Waters Corporation, Milford, MA, USA
Co-author: Michael Swartz
Method validation is a tedious process performed to
determine if an analytical method meets the require-
ments for its intended purpose. In the regulated labora-
tory, method validation may take many days to perform
the necessary analytical tests. Data reduction and the
statistical analysis of results performed can be a very
time-consuming process. There is also a greater poss-
ibility of introducing error when calculations are per-
formed manually. With the use of automated software to
perform these calculations, method validation is much
faster and easier, with less chance for error.
In this poster, we will show that an analytical method
was validated using automated software. Chromato-
graphic results were directly accessed from a relational
database bypassing manual intervention. Statistical cal-
culations were performed automatically and a report
generated showing the results of the analyses from the
Student, Cochran, Dixon and Fisher tests. Graphs were
generated representing the results of the statistical analy-
sis. In addition, we will show that the data reduction and
statistical calculations necessary to validate the method,
complete with the necessary documentation and report
generation, are completed in signi® cantly less time.
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HPLC techniques
Patricia A. Fowler, Waters Corporation, Milford, MA, USA
Co-authors: Kelly A. Johnson, Michael E. Swartz and Charles
H. Frasier
The fast pace of the pharmaceutical industry requires
laboratories to reduce the analytical burden of their
test procedures and increase productivity while still
satisfying regulatory compliance. There are several ways -
to meet these challenges in the dissolution laboratory.
By automating the dissolution process, pharmaceutical
laboratories eliminate the slight variations that may
occur in manual methods, insuring reproducible
data, higher throughput and cost reduction. Vali-
dated single-source software control of the entire
system, as well as dissolution data acquisition, calcu-
lations and reporting, can further streamline the work
¯ ow while maintaining FDA compliance with 21 CFR
Part 11.
Automated online HPLC dissolution systems can
pool dissolution samples signi® cantly to save time.
Similarly, automated sampling at shorter intervals
and analysis of a large number of samples by online
HPLC may provide a more complete solution for
the decision-making process in the early stages of
drug development. In addition, these systems must be
capable of handling increasingly complex formulations
such as multiple actives and widely varying dosage levels,
as well as diå erent media types such as buå ers and
surfactants.
Our poster shows applications used to help reduce the
analytical burden and increase the sample throughput
and productivity in the laboratory.
Homogeneous high-throughput SNP assay direct
from genomic DNA
Patrick B. Cahill, Genome Therapeutics Corporation, Waltham,
MA, USA
Co-authors: Dina Weymouth, Cori Gustafson, James Hurley,
Michele Bakis, Veena Kamath, Doug Smith and Lynn Doucette-
Stamm
Genome Therapeutics Corp has developed a
high-throughput SNP assay based on the ability of
some DNA polymerases to proofread the sequence
as they extend. This Exo-Proofreading SNP assay
can be accomplished, from sample addition to detection,
in one tube. In addition, this SNP assay has the
capability to be performed directly on genomic
DNA. Results will be presented for this assay on multiple
SNPs screened on large populations. The results will
be compared with ASO and RFLP data with dis-
crepancies resolved by sequencing. This assay provides
a new, highly robust and fast method for large-scale SNP
screening required for human disease and pharmacoge-
netic studies.
Development of a lead identi￿ cation platform for
kinase drug discovery
Paul Gallant, Millennium Pharmaceuticals, Inc., Cambridge,
MA, USA
The goal of any drug-discovery process is to eliminate
quickly ` poor’ leads while rapidly advancing those with
the highest potential. Millennium has used a combina-
tion of novel and mature technologies to establish a
system to progress novel kinase targets rapidly through
assay development, high-throughput screening, hit vali-
dation and hit characterization. By selecting focused
technologies, automation, secondary screens and IT, an
integrated process has been constructed which is capable
of handling multiple targets quickly while identifying the
compounds with the highest potential for lead optimiza-
tion. This presentation will discuss the platforms chosen
for assay development, high-throughput screening, hit
con® rmation and potency/selectivity determinations. A
process will be described to show how using a standard
well-de® ned system can eå ectively move multiple kinase
targets rapidly into the ` Lead Optimization’ stage.
Optimization and automation of bioanalytical
methods
Peter D. Bryan, Forest Laboratories, Abbott Park, IL, USA
Co-authors: Min S. Chang and Anita Shen
Now that LC-MS has become the technique of choice in
the GLP bioanalytical laboratory, the work¯ ow bottle-
neck has shifted from the separation± detection to the
sample-processing portion of the bioanalytical method.
To address the sample-processing bottleneck, eå orts have
been concentrated on the conversion and validation of
existing liquid± liquid extraction (LLE) to solid-phase
extraction (SPE) methods. Profound increases in sample
throughput have been achieved using LC-MS with
automated SPE in the 96-well format over manual
LLE extraction HPLC methods. Validation of auto-
mated 96-well format SPE methods have shown their
equivalence to manual LLE extraction. Automated 96-
well format SPE is also much less tedious and allows the
analyst to concentrate more on data analysis and com-
pliance issues. For routine analysis, transfer from clinical
tubes to the 96-well format has been accomplished using
either the Biomek 2000 or the Hamilton MicroLab AT.
Automated SPE is then performed on the Biomek 2000.
Additionally, semi-automated method development for
96-well format SPE has been automated using the
Biomek 2000.
How small is enough?
Peter Grandsard, Amgen, Inc., Thousand Oaks, CA, USA
Co-authors: Jim Petersen, Brian Rasnow, Mike Johnson, Chuck
Li, Les Walling and Doug Overland
A signi® cant technical and organizational challenge
facing the biopharmaceutical industry is the incorpora-
tion of miniaturization technologies into their business.
The successful application of these technologies requires
answers to the following questions. What is this new
miniaturization technology? Which technologies should
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be implemented? Should a technology be implemented
early, through some sort of technology access programme
(TAP), or should one wait until it becomes commercially
available? Our views on these matters will be presented.
In collaboration with other Amgen R&D groups, the
Research & Automation Technologies department has
been actively cultivating critical collaborators with
knowledge of submicrolitre liquid-handling, microma-
chining and detection technologies. For example, our
TAP with Caliper, Inc., has increased our institutional
understanding of miniaturization applications in the
drug-discovery process ¯ ow, most particularly in small
molecule screening and DNA analysis.
Miniaturization at Amgen has invoked a cascade of new
projects or at least studies. The goals of these projects are
to ® nd solutions for interfacing any miniaturized plat-
form to the ` macro-world’ , such that the advantages of
miniaturization are not undone by integration or certain
interfaces. Operations that need to undergo changes to
bene® t fully from miniaturization include the storage and
retrieval of small molecules, detection and compound
handling during screening, and information manage-
ment. We will discuss some of our ® ndings and solutions.
Automation and tracking of combinatorial
libraries
Phil Small, Tripos Receptor Research, Bude, UK
A process-integrating design, synthesis and analysis of
combinatorial libraries has been implemented at Tripos
Receptor Research. Crucial to the success of this process
has been the development of a proprietary informatics
system. This has so far been developed to manage reagent
inventory, track samples, and record data from synthesis
and analysis to provide a valuable database of compound
information.
The combination of Tripos’ s proprietary design software
with automated synthesis and informatics leads to the
production of drug-like libraries with well-de® ned purity
and full synthetic history.
This presentation will cover what were considered the
important aspects involved in setting up and managing
an automated chemistry facility.
Automating pH solubility and stability determina-
tions conducted in support of early development
Phil Waters, GlaxoSmithKline, Research Triangle Park, NC,
USA
Co-authors: James Ormand, David Igo and Pingyun Chen
Evaluation of the equilibrium solubility and chemical
stability of compounds as a function of pH aids our
understanding of the bioavailability of a drug candidate.
Additionally, these data lead to rapid development of
formulations for use in preclinical and clinical studies.
Conducting these measurements often requires a signi® -
cant amount of human labour and time. Reducing the
labour and time burden is expected to increase the
frequency with which these measurements can be ap-
plied, thus increasing sample throughput and improving
the quality of decisions impacting compound selection
and evaluation.
This presentation will describe sample-handling method-
ologies and automated instrumentation developed to
conduct solubility measurements as a function of pH.
The use of these methodologies and instrumentation has
improved both throughput and eæ ciency while main-
taining the accuracy that can be achieved with manual
methods. The accuracy and precision of the system will
be illustrated using data on model compounds as well as
drug candidates. Finally, we will describe the strategy
and process used to prepare samples for stability deter-
minations at user-de® ned pHs, and how this process is
done in concert with the solubility determinations.
Development of novel micro-array technology for
cell-based assays
Quiyang Zhang, Cytoplex Biosciences, Plano, TX, USA
Co-author: Alex Freeman
Cell-based assays are increasingly used for high-through-
put screening in drug-discovery programmes because
of their high information content. For the implementa-
tion of miniaturized cell assay, micro-arraying is an
essential part of the technology. Initially, we had per-
formed cell-adhesion studies and evaluated ® ve diå erent
substratesÐ polystyrene, polycarbonate, silicon, glass and
PDMSÐ and found that with polylysine coating, the
glass, silicon and PDMS substrates served well for cell
attachment. However, the conventional well-less spotting
and assaying method was diæ cult to implement in
producing a predetermined array pattern of cells.
To overcome the above diæ culty, we further developed
both bottomed and bottomless well arrays to address the
need for cell culturing and assays. PDMS and glass were
used as the bottom surfaces for both bottomless well
silicon substrates and bottomed wells. Novel liquid distri-
bution arrays were fabricated in silicon to facilitate initial
coating and liquid exchange from the entire array. The
arrays were implemented for culture of adherent and
non-adherent cells, immunochemical assays, and auto-
matic liquid transfer all in high-density format. The
current array platform will be also useful in cell library
construction, combinatorial library synthesis, and con-
tinuous homogeneous and heterogeneous assays.
Adaptive powder-dispensing system
Rajesh K. Maheshwari, Schering-Plough Research Institute,
Union, NJ, USA
Co-authors: Annaniy Berenshteyn, Gary Kowalski and Joseph
Norgard
This poster is about a robotic powder dispensing system
we have developed. It can dispense on average
10mg § 5% from any of the 288 dispensers on its
carousel, into a sealed 24/96-well deep-well microtitre
plate. The powders are kept in a sealed environment and
are diå erentiated for dispensing purposes by their
dispensing parameters, which are stored by in a
Microsoft Access database. The database entry is pointed
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dispensing.
The user interface for this multiprocessor system consists
of 250000 lines of Multithreaded/Multitasking Visual
C‡‡ code. An Access database holds dispensing
parameters’ information for each powder. A Dynamic
Query Screen has been designed to make it easy for a
chemist to view the database selectively.
Such a system can ® nd other uses such as distributing
compounds in the compound distribution centre, dispen-
sing lyophalized microorganisms, dispensing resins for
combinatorial chemistry, and any other application
when powder is to be delivered precisely in a controlled
environment.
Automated system for compound library screen-
ing by MTS cell-viability assays
Randall Engler, Kendro Lab Products, Newtown, CT, USA
Co-authors: C. Elliot and R. Moody
Cell proliferation, cytotoxicity and other viability assays
play an important role the drug-discovery process. Many
screening programmes target anticancer compounds,
requiring in-vitro characterization of eæ cacy. Addition-
ally, all potential therapeutic compounds must be char-
acterized for their cytotoxicity regardless of the target
(ADME/Tox).
Cytokinetics has developed a system to automate the
process of reagent addition, incubation and reading
of cell viability assays using the MTS method of
Promega, Inc. The integrated system includes hardware
from a variety of sources and software developed by
Cytokinetics.
Control of environmental conditions including CO2,
temperature and humidity are important factors in
accurate and reproducible cell-based assays. The system
described here includes the Heraeus
1 Cytomat
1 6000
series incubator from Kendro for the incubation of cells.
Automation development for high-throughput
phage library screening
Randy Yen, Genentech, Inc., San Francisco, CA, USA
Co-authors: Sherry Yeh and Suki Hyare
Phage display technology is a powerful tool in genomic
and drug development. It allows scientists to screen
quickly billions of peptides, antibodies and cellular
proteins for binding to a target. It is a vital tool in studies
aimed at identifying molecules that bind to a speci® c
target and at improving particular features of pre-exist-
ing molecules. At Genentech, we automated the binding
assays for the speci® c target to screening the phage
library. By running fully automated 384-well assay on
the robotic system, we screened thousands of clones in a
multiple target in 1 day and ® nished each library in a
short time.
Comparison and contrast of di´ erent dissolution-
sampling systems using the Agilent 8453 UV-VIS
in a QC laboratory
Reem Malki, Andrx Pharmaceutical, Fort Lauderdale, FL, USA
Co-author: Michael K. Michaels
An integral part of an eæ cient QC laboratory is thorough
planning. With a new facility about to open and many
diverse projects in the pipeline, the proper approach to a
successful implementation is to think, research, plan,
budget, set up, test, comply and train.
We knew as a laboratory that we could not function with
only one type of dissolution system. Our research led us to
two automated options. The ® rst, a peristaltic pump
sampling system using a single-¯ ow cell approach, oå ers
the detection of the sample. The second, a syringe pump
sampling system using a multi¯ ow cell approach, pro-
vided us the options to detect, detect and collect, and
collect and dilute the sample. Each of these dissolution
set-ups is paired with an HP8453 UV-VIS while remain-
ing 21 CFR Part 11 compliant.
Cross-functional team approach to implementing
and managing laboratory automation in the qual-
ity control laboratory
Timothy Reilly, Novartis Pharmaceutical Corporation, Su¡ern,
NY, USA
Poorly de® ned project goals and an inadequate infra-
structure have hindered previous attempts to initiate
automation projects in the Novartis Quality Control
laboratory. This haphazard approach has been replaced
with well-de® ned project expectations and agreement
among the functional groups that make up the project
infrastructure to support aggressively the automation
project goals.
New concept for automation of dissolution tests
for biowaiver studies
Rolf Rolli, Sotax Ltd, Allschwil, Switzerland
New FDA regulations allow biowaivers for Class I drugs
based on solubility, permeability and dissolution testing.
BCS-based biowaivers can be requested for signi® cant
post-approval changes (e.g. Level 3 changes in com-
ponents and compositions) to a rapidly dissolving im-
mediate release product containing a highly soluble,
highly permeable drug substance, provided that dissolu-
tion remains rapid for the post-change product and both
pre-/post-change products exhibit similar dissolution
pro® les. Dissolution tests have to be performed at pHs
1, 4.5 and 6.8. With this regulation, automation of
dissolution testing gains further importance with respect
to pH changes.
A fully automated test system with the necessary software
is described. This solution oå ers one the capability to run
up to 15 USP 2 tests in series. With such a system, all
steps are fully automated, from medium preparation, to
tablet input and up to the printout of the reports. The
system includes a very eæ cient cleaning device that
prevents any carry-over between tests. Tests requiring
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allows up to 10 USP 1 tests to be analysed. With this
automated dissolution concept, biowaiver studies are
executed rapidly allowing for accelerated drug develop-
ment and SUPAC changes.
Integration of reagent management and computa-
tionally biased combinatorial synthesis
Scott M. Harris, DuPont Pharmaceuticals Research Labora-
tories, San Diego, CA, USA
One of the key aspects to successful high-throughput drug
discovery is the ability to integrate several functions.
These include medicinal chemistry, computational de-
sign, high-throughput synthesis and puri® cation. A po-
tential bottleneck in this process is a lack of established
chemistries linked with readily available commercial and
proprietary building blocks. Early in the process, it is
critical that a protocol exists that allows for planning and
synthesizing libraries, developing initial structure± activ-
ity relationships and validating screening leads.
It is also important to have access to novel building
blocks and reagents for preparing targeted or focused
libraries. DuPont Pharmaceuticals has developed a
simple custom Web-based monomer request system that
uses a JAVA GUI that allows for tracking of orders and
report generation. The data are housed in a Reagent
Inventory Tracking System using Oracle and the physi-
cal reagents are stored in a controlled ventilated cabinet
system. The typical throughput and average turn around
time will be discussed. The overall bene® ts of this
programme are lower costs, better inventory control
and an increase in eæ ciency in library production and
chemistry.
Automation of chemistry in a core DNA-sequen-
cing facility
Shawn Hallowell, P¢zer Global R&D, Groton, CT, USA
Co-authors: Suzanne P. Williams, Yevette C. Clancy, Melissa
T. Cronan, Shawn E. Hallowell, Michael Polchanino¡, Lance
Ryley and Janice L. Palmer
Conversion of our core DNA sequencing laboratory to
the 3700 DNA analyser (AB) and sequencer for BioLIMS
sequence analysis and database software (AB, genecodes)
has greatly reduced the amount of manual intervention
required for generating, analysing and maintaining DNA
sequence data.
The set-up of the DNA sequencing reaction is the next
process that has been selected for improvement. Cur-
rently, requests for sequencing from the Therapeutic
Area laboratories are (1) submitted online, (2) the
sample information is transferred to the 3700 plate record
and (3) the addition of DNA and primers to the thermal
cycle plate is performed manually.
Manual chemistry requires up to 4h of hands-on time per
day depending on the number of samples. While a liquid
handler working oå a ® le can perform the hit-picking
required for core terminator chemistry, the set-up of
the source racks is time-consuming and a possible source
of errors. The poster will present the use of Web
submission, individually bar-coded sample tubes and a
liquid handler for automating chemistry set-up in a core
DNA sequencing facility.
Micro-array process industrialization
Shane Weber, Millennium Pharmaceuticals, Cambridge, MA,
USA
Millennium’ s nylon cDNA micro-array platform is suc-
cessfully ® lling our drug- and marker-discovery plat-
forms. This platform is eå ective because of its
sensitivity, gene content, throughput eæ ciency and cost.
The platform’ s eå ectiveness results from the industria-
lized process ¯ ow of liquid handling, printing and
information tracking. Eå ectiveness is constantly assessed
by measurements of quality and eæ ciency. The process
¯ ow and quality assessment will be reviewed.
Mass-directed puri￿ cation of combichem
libraries
William R. Hall, GlaxoSmithKline, Research Triangle Park,
NC, USA
Co-authors: Melissa Lindsay and Dean Phelps
The Library Puri® cation Group at Research Triangle
Park is responsible for puri® cation of both large and
small libraries from discovery and targeted research.
We use mass-directed preparative HPLC to purify
library samples with masses of 5± 100mg per well. Our
system incorporates at-column dilution, separate waste
collection for each sample and UV veri® cation of peak
collection. Eæ cient evaporation of solvents, robotic li-
quid handling and reformatting, and fast QC on puri® ed
samples allows for high-throughput of puri® ed libraries.
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Myers Squibb Automated Screening Core
Steven F. Innaimo, Bristol Myers Squibb PRI, Wallingford,
CT, USA
As part of the evolution and industrialization of the BMS
Lead Discovery organization, a core group of specialized
scientists focused solely on automated screening was
assembled. The mission of the Automated Screening Core
is to adapt and prosecute high-throughput screen cam-
paigns on fully automated robotic screening systems.
This talk will cover the implementation of the BMS
automated screening infrastructure, the rationale for
the establishment of the Automated Screening Core
and the organizational impact of such a group.
Determining feasibility and parameter values for
compound orders based on transfer amounts,
liquid-handler capabilities and container-volume
capacities
Steven Ho¡man, Bristol-Myers Squibb PRI, Princeton, NJ,
USA
Co-author: Mark F. Russo
An algorithm is described for determining the feasibility
and calculating parameter values for one or more
compound processing orders. Feasibility is determined
primarily by applying a series of inequality constraints
that result in a valid target concentration range within
which orders can be processed. These inequality con-
straints are obtained from initial compound amounts,
source and destination container-volume capacities, the
liquid-handler transfer volume range and the amount of
compound to be processed. If feasible, calculated par-
ameter values include the dilution, transfer and top-oå
volumes necessary to ful® l the order. Sample code
implementing the algorithm is given in Microsoft Visual
Basic
1.
High-throughput screen to detect inhibitors of the
30-50-HCMV exonuclease
Steven J. Conrad, Pharmacia Corporation, Kalamazoo, MI,
USA
Co-authors: Thomas W. Pitts, Nancee Oien, Robert A. Anstadt,
Roger A. Poorman, Peter A. Wells, Michael W. Wathen and
Yoshihiko Yagi
We carried out a ¯ uorescence polarization-based (FP)
high-throughput screen (HTS) to detect inhibitors of the
30-50-exonuclease activity of the human cytomegalovirus
DNA polymerase (the HCMV exonuclease). We used a
23-mer ssDNA substrate labelled with TAMRA at the 30
end. The emitted light from TAMRA in an intact
substrate molecule was highly polarized (about
240mP), but, upon substrate digestion with the HCMV
exonuclease, the emission from TAMRA free in solution
exhibited a lower polarization (about 40mP).
The assay was designed to run in a 384-well format with
a ® nal volume of 50ml. The Km of the HCMV exonu-
clease for the substrate was determined to be 20 nm. In
the assay, 50nm substrate was digested by 0:01 £ stock
HCMV exonuclease in 50mm HEPES, pH7.6, which
produced a 50% reduction in mP in 8.3min. We
screened 117 843 compounds at 10mm (2.5% DMSO).
The screen identi® ed 647 compounds that inhibited the
HCMV exonuclease
3 30%.
High-throughput protein function screening for
immune system target validation
Stewart D. Chipman, Immunex, Corporation, Seattle, WA, USA
Validation of the biochemical function of a novel gene/
protein in the pathophysiology of a disease is the rate-
limiting step in novel target validation for drug discov-
ery. Many groups have applied the technology and
methodology developed for small molecule high-through-
put screening and clinical testing to assays that test for
novel protein function. This presentation will address
how we have integrated gene discovery and expression
analysis, protein production and inventory capability,
cell-based protein function assays, laboratory automation
tools and data management systems into an integrated
target discovery and validation platform for immune
system targets. Topics to be discussed are automated
and multiplexed cytokine detection, cognate ligand
detection, calcium mobilization, high-throughput optical
imaging, large-scale cell preparation, large-scale protein
expression and puri® cation, workstation style laboratory
automation and automated data handling.
Laboratory automation: a cost-e´ ective solution
to increasing laboratory workloads
Stephen Green, Forest Laboratories Ireland Ltd, Dublin, Ireland
Forest Laboratories, Inc., markets Celexa, an SSRI
antidepressant, in the USA. The bulk tablets are pro-
duced at the manufacturing site in Dublin, Ireland.
Market projections in 1999 indicated a 250% increase
in volumes to be produced at the Dublin site. Several
laboratory strategies to cope with this increased produc-
tion were assessed and the use of automated robotic
systems was shown to be the most cost-eå ective solution.
The introduction of the automation into the laboratory
had several phases. Initially, there were physical changes
required to the laboratory layout to accommodate the
robots. Second, there was the quali® cation of the robotic
systems and the training of the initial users. Finally, there
was the development and validation of several analytical
methods, which was performed in conjunction with the
Zymark MTOV group.
Characterization and e´ ective use of the molecu-
lar properties of reaction vessel surfaces in
high-throughput assay development
Sven Erik Rasmussen, Nalge Nunc International, Naperville, IL,
USA
Co-author: Nalge Nunc
An understanding of the molecular surface of a reaction
vessel is critical to achieving the sensitivity and speci® city
for high-throughput or high-content molecular and cell-
based assays. We developed and characterized several
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tively used in genomic and proteomic assays. These
surfaces, in conjunction with the physical properties of
the substrate material (optical or thermal properties, for
example) along with format (MicroWell, slide, or chip),
are compared with regard to assay performance.
Through XPS analysis (also known as ESCA), the mol-
ecular and atomic compositions of various MicroWell
surfaces have been de® ned. These data will be used to
demonstrate the speci® c utilization of the surface in
molecular and cell-based assays. For example, a hydro-
philic, highly charged surface, MultiSorp, preferentially
binds complex phospholipid molecules while excluding
other molecules, including glycoproteins such as IgG.
Another ` high-binding’ hydrophilic surface, MaxiSorp,
binds a signi® cant amount of glycoproteins such as
immunoglobins. These surfaces and others such as
the Nunclon Delta cell culture surface and non-treated
sterile polystyrene surfaces are molecularly de® ned by
ESCA techniques accompanied by speci® c procedural
examples.
Well geometry, round, square, columnar or ` shallow’ ,
in¯ uences assay performance, particularly when an ac-
tive surface is used. Additional parameters come into
eå ect when well volumes are miniaturized as in a 1536-
well plate. The eå ect of a molecular surface changes
again as the assay is further miniaturized to a two-
dimensional format as in a slide or chip and the in¯ uence
of the substrate material may increase.
Also important to the development of a speci® c, sensitive
and eæ cient assay are the physical characteristics of
various substrate materials. With regard to optical prop-
erties, the ¯ uorescent and re¯ ective properties of solid
black and solid white as well as black or white optical
bottom plates (OBP) were compared by measuring
signal-to-noise ratios, light cross talk and sensitivity. Data
and practical applications will be discussed.
New polymer substrate for DNA micro-arrays
Svend Erik Rasmussen, Nalge Nunc International, Naperville,
IL, USA
Co-authors: T. Kristensen, K. HolmstrÖm and L. Pedersen
The quality and surface properties of the micro-array
substrates are fundamental factors for a successful DNA
micro-array system. At present, coated glass-slides
(amine-, alehyde- or epoxy-coated) are the dominating
substrates on the market. However, an often-encountered
problem using these substrates is a non-homogenous
surface, which can lead to problems with spot uniformity
and morphology. Nunc A/S has developed a pre-acti-
vated, but uncoated, NucleoLink
TM polymer MicroAr-
ray Slide that can be used, without any further
modi® cation, for creating DNA micro-arrays. The Nu-
cleoLink
TM polymer MicroArray Slide can be used for
both covalent attachment of DNA as well as immobiliza-
tion of DNA by electrostatic forces and/or ionic bonds.
Studies of auto¯ uorescence properties, DNA-binding ca-
pacity and DNA-hybridization eæ ciency have been
performed and compared with conventional glass sub-
strates. Data from oligonucleotide arrays as well as cDNA
arrays will be presented.
Flexibility paradigm in laboratory automation
management
T. C. Ramaraj, Roche Discovery Technologies, Ho¡mann-La
Roche, Nutley, NJ, USA
Considerable developments and rapid changes have
taken place in high-throughput screening and compound
management in the last 5 years. This is a result of a
concerted eå ort between the pharmaceutical industry,
laboratory automation companies, instrument companies
and manufacturers of consumable laboratory ware. The
evolution of new automation technologies has fuelled the
growth and prospects for various modes of automation in
virtually all phases of drug-discovery research. Here, we
will try to highlight our experiences in managing a
complex HTS and compound management infrastruc-
ture at Hoå mann-La Roche.
The infrastructure consists of automation platforms that
have evolved over several years. All require proper care
and maintenance for sustained performance. Some re-
cently installed con® gurations require continued valida-
tion to achieve expected levels of performance and
reliability to match ever-increasing throughput require-
ments. Promising new automated screening technologies
require careful evaluation. Validation of these new tech-
nologies also require allocation of signi® cant resources for
meeting demanding requirements of miniaturization,
speed, ¯ exibility, cost eæ ciency and increased perform-
ance levels. It is no easy task to steer winning method-
ologies to their fullest potential and at the same time take
a risk in exploring unproven avenues and technologies.
To maintain a balanced perspective among available
choices requires ¯ exibility in approach, quick implemen-
tation strategies, a diverse pool of expertise and talent
that can work as a team, contribute as individuals, share
the successes as well as failures, learn from the mistakes,
revise the expectations and still meet corporate goals and
objectives every year. The presentation will also include
examples from some of our most recent integration
experiences, the upgrade of existing systems, the imple-
mentation of new detection modes in existing instruments
and our experience with latest 384-well pipetting systems.
Variety of automation tools for drug metabolism
Thomas Lloyd, DuPont Pharmaceutical Co., Newark, DE, USA
Automation continues to be developed for new diversi® ed
applications within drug metabolism. The choice of an
automated tool can vary considerably depending on the
speci® c requirements of the application. An overview of
the automated tools that have been introduced at
DuPont over the last 5 years will be presented along
with speci® c application examples. An evaluation is
oå ered for how the diå erent tools have proliferated
throughout this function.
Automation application areas include bioanalytical
sample preparation techniques including solid-phase
extraction, liquid± liquid extraction, protein precipitation
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preparation processes, sample handling, data handling
and training. Application areas include many functions
within drug metabolism ranging from discovery through
clinical trials.
Characterization and e´ ective use of the molecu-
lar properties of reaction vessel surfaces to
achieve optimal assay performance
Tom Cummins, Nalge Nunc International, Rochester, NY, USA
Co-authors: Janne N. Knudsen, Lena B. Larsen, Svend Erik
Rasmussen, Tom Cummins and Joseph Granchelli
An understanding of the molecular surface of a reaction
vessel is critical to achieving the sensitivity and speci® city
for high-throughput or high-content molecular- and cell-
based assays. We developed and characterized several
molecular surfaces for reaction vessels that can be used
eå ectively in genomic and proteomic assays. These
surfaces, in conjunction with the physical properties of
the substrate material (optical or thermal properties, for
example) along with the format, are compared with
regard to assay performance.
Through ESCA analysis, the molecular and atomic
compositions of various MicroWell
1 surfaces have been
de® ned. These data will be used to demonstrate the
speci® c use of the surface in molecular and cell-based
assays. For example, a hydrophilic, highly charged sur-
face preferentially binds complex phospholipid molecules
while excluding other molecules, including glycoproteins
such as IgG. Another ` high-binding’ hydrophilic surface,
MaxiSorp
TM, binds a signi® cant amount of glycoproteins
such as immunoglobins.
Well geometry, round, square, columnar or ` shallow’ ,
in¯ uences assay performance, particularly when an ac-
tive surface is used. Additional parameters come into
eå ect when well volumes are miniaturized as in a 1536-
well plate.
Also important to the development of a speci® c, sensitive
and eæ cient assay are the physical characteristics of
various substrate materials. With regard to optical prop-
erties, the ¯ uorescent and re¯ ective properties of solid
black and solid white as well as black or white optical
bottom plates (OBP) were compared by measuring
signal-to-noise ratios, light cross-talk and sensitivity.
Data and practical applications will be discussed.
Intelligent automated dissolution system! A
challenge worth striving for
Umesh V. Banakar, Pharm-Assist International, Carmel, IN,
USA
Co-author: Manoj Bagool
Dissolution testing requirements have been extended to
all oral dosage forms over the past decade. Additionally,
the dissolution regulations for pharmaceutical formula-
tions have been tightened world-wide. Furthermore, the
past decade has also witnessed an increase in popularity
of modi® ed release pharmaceuticals that inherently re-
quire extended dissolution protocols. The increased
emphasis on correlating dissolution and bioavailability
data points to the desirability of more frequent sampling
points to validate a dissolution pro® le. As a result, these
developments have signi® cantly increased the require-
ments of equipment, personnel, data processing and
validation, which translates into increased production
time for oral dosage forms. Thus, automation in dissolu-
tion testing has become a necessity in order to handle
these demands.
Automation in dissolution testing is not new to the
pharmaceutical industry. Simultaneous to the develop-
ment in pharmaceutical technology over the past decade,
there have been advances in automated dissolution
testing, although at a slower pace. The virtual explosion
in the diverse and yet speci® c requirements associated
with a plethora of dosage form types and their respective
functions have curtailed the outright all-encompassing
development in automated dissolution testing. While the
advantages of automated dissolution testing are unequi-
vocal, the limitations of automated dissolution testing
systems cannot be refuted. There is a constant quest to
improve an existing automated system that meets speci® c
requirements, either a unit function of the test or to
accomplish a speci® c expectation of a dosage form, thus
limiting the universality of the automated system.
Robert Kennedy once said, ` Some people watch things
happen and ask the question, why; and there are those
that dream of things and ask the question, why not!’ It is
beyond doubt that an automated dissolution testing
system that addresses the current limitations of the
existing ones and yet is ¯ exible and universal enough is
the need of the day. Going beyond the minimum
expectations of such an automated dissolution test into
its utility during early drug development and above all in
simultaneous prediction of bioavailability, can be a
dream worth striving for. A vision for such an automated
dissolution test system will be presented.
Development of a radiofrequency identi￿ cation
(RFID) data carrier interface with an analytical
balance
Je¡rey Veitch, GlaxoSmithKline, Ware, UK
Co-authors: Tony Allcock and James Ormand
The use of process instrumentation such as analytical
balances within the laboratory is commonplace and the
need for capturing related process measurement data are
often a necessity. Quite often these data need to be
exported to databases and invariably to laboratory
information management systems (LIMS). Laboratories
regularly use process equipment such as balances, pH
meters, etc. that are not attached to a dedicated PC. At
GlaxoSmithKline, we have developed a way of capturing
process data (e.g. weight values) directly to radiofre-
quency identi® cation (RFID) smart labels, where these
labels are used as data carriers.
This evaluation has proven to be a success and is
potentially the stepping stone towards a more speci® c
use of RFID within GlaxoSmithKline.
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workstations
Achim Wehren, QIAGEN Hilden, Germany, and Valencia, CA,
USA
Co-authors: Fred Siegmanand Carola Schade
Automated robotic workstations are frequently used as
stand-alone systems for sample puri® cation, reaction set-
up or sample re-array in the ® eld of genomics. However,
a variety of external instruments often must be integrated
to provide full automation of several sequential tasks or to
increase the range of applications that can be performed.
QIAGEN
1 Instruments provides complete solutions
to automate molecular biology and liquid-handling
applications by integrating BioRobot workstations
with a wide range of accessory instruments, including
thermal cyclers, spectrophotometers and the BioRobot
RapidPlate
1, a 96-channel pipetting system with cap-
abilities for both 96- and 384-well pipetting. These
integrated systems provide rapid and fully automated
processing for applications such as DNA template nor-
malization, PCR, sequencing reaction set-up and sample
transfer tasks.
BioRobot
1 3000 extended-arm systems are designed
to accommodate complementary instruments on both
the left and right sides. Additional integration of
the BioRobot Twister
TM increases system storage ca-
pacity for microplates, blocks and disposable tips, and
allows the integration of accessory instruments with both
extended-arm and standard BioRobot workstation con-
® gurations.
BioRobot
1 8000 robotic workstations can be integrated
with accessory instruments using the BioRobot Twister II
external arm for walkaway front-end processing, e.g.
from plasmid puri® cation to ® nal reaction set-up. The
large size of the BioRobot 8000 worktable and the high
storage capacity of the Twister II robotic arm allow
unattended operation over extended periods.
QIAsoft
TM, the BioRobot Operating System, commu-
nicates with external instrument software, controls pro-
cesses performed on the BioRobot and coordinates the
actions of the BioRobot and external instruments.
Dispensing precision for the SciClone
TM auto-
mated liquid-handling workstation for 96-channel
pipetting
Rudy Willebrords, Janssen Research Foundation, Beerse,
Belgium
One of the ® rst steps in drug discovery involves identi® ca-
tion of novel compounds that interfere with therapeuti-
cally relevant biological processes. Identi® cation of ` lead’
compounds in all therapeutic areas included in a drug-
discovery programme requires labour-intensive evalua-
tion of numerous samples in a battery of therapy-targeted
biological assays. To accelerate the identi® cation of lead
compounds, JRF has developed an automated high-
throughput screening (HTS) based on the unattended
operation of a custom Zymark-tracked robot system.
Automation of enzymatic and cellular assays was realized
with this system adapted to the handling of microtitre
plates. The microtitre-plate technology is the basis of our
screening. All compounds within our chemical library are
stored and distributed in micronic tube racks or micro-
titre plates for screening. An eæ cient in-house-developed
mainframe-based laboratory information management
system supported all screening activities. Our experience
at JRF has shown that the preparation of test compounds
and making serial dilutions have been rate-limiting steps
in the overall screening process. To increase compound
throughput, it was necessary both to optimize the
robotized assays and automate the compound supply
processes. In HTS applications, one of the primary
requirements is highly accurate and precise pipetting
of microlitre volumes of samples into microplates.
The SciClone
TM is an automated liquid-handling work-
station capable of both 96- and 384-channel high-preci-
sion pipetting. For high-throughput applications, the
SciClone
TM instrumentation can pipette a variety of
liquid solutions with a high degree of accuracy and
precision between microplates (interplate variability)
and tip-to-tip (intraplate variability) within a single
plate. The focus of this presentation is to review the
liquid-handling performance of the SciClone
TM system
as a multipurpose instrument for pipetting aqueous or
organic solutions, and virus suspensions into 96- and 384-
well microplates. The capabilities of the system and the
resulting bene® ts for our screening activities will be
described.
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